

## Curriculum Vitae

**Date Updated:** June 10, 2022

**Office Address:** University of Cincinnati College of Medicine  
Division of Digestive Diseases  
231 Albert Sabin Way  
Cincinnati, OH 45267-0595

### Education

1976	B.S.	Microbiology	Rutgers University, New Brunswick, NJ
1980	PhD	Microbiology	Rutgers University, New Brunswick, NJ (Mentor: Karl Maramorosch, PhD)
1985	MD	Medicine	George Washington University, Washington, D.C.

### Postdoctoral Training

07/80-06/82	Research Fellow, Transmissible Disease and Immunology Lab American Red Cross National Blood Research Center (Mentor: Roger Dodd, PhD) Bethesda, MD	
07/85-07/88	Intern and Resident in Internal Medicine Tripler Army Medical Center	Honolulu, HI
07/89-06/91	Fellow in Gastroenterology/Hepatology Fitzsimons Army Medical Center (Hepatology/Liver Transplantation at University of Colorado Health Sciences Center, Denver, CO)	Denver, CO

### Faculty Academic Appointments

1978-1980	Adjunct Faculty	Biology	Middlesex College	Edison, NJ
1988-1989	Assistant Clinical Professor	Medicine	University of Hawaii SOM	Honolulu, HI
1991-1994	Assistant Clinical Professor	Medicine	University of Colorado SOM	Denver, CO
1994-2002	Associate Professor	Medicine	University of Cincinnati COM	Cincinnati, OH
2002-	Professor	Medicine	University of Cincinnati COM	Cincinnati, OH

### Appointments at Hospitals/Affiliated Institutions

#### Past

07/88-6/89	Physician, Active Staff	Medicine	Tripler Army Medical Center, Honolulu, HI
07/91-5/94	Physician, Active Staff	Medicine	Fitzsimons Army Medical Center, Denver, CO

#### Present

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

07/91-06/94	Physician, Active Staff	Gastroenterology	Fitzsimons Army Medical Center, Denver, CO
08/94-	Physician, Active Staff	Gastroenterology	University Hospital, Cincinnati, OH
08/94-	Consultant Staff	Gastroenterology	Cincinnati VA Hospital, Cincinnati, OH
08/98-	Consultant Staff	Gastroenterology	Cincinnati Children's Hospital, Cincinnati, OH

### Other Professional Positions

2006	Consultant, Advisory Board	Idenix, Boston, MA
2006-2010	Consultant	SciClone Pharmaceuticals, Foster City, CA
2007-2011	Consultant/Advisory Board	Bristol Myers Squibb, Wallingford, CT
2008	Consultant	Astellas US LLC, Deerfield, IL
2008-2011	Consultant/Endpoint Adjudication	Pfizer, Collegeville, PA
2008-2018	Consultant/Advisory Board	Merck, North Wales, PA
2008-2010	Consultant/Advisory Board	Vertex, Cambridge, MA
2009	Consultant	Valeant, Aliso Viejo, CA
2009-2012	Chair, Data Safety Monitoring Board	Tibotec/Janssen
2010	Consultant/Advisory Board	Regulus, San Diego, CA
2010-	Consultant/DSMB	MedPace, Cincinnati, OH
2011	Consultant/Advisory Board	Roche Molecular Systems, Pleasanton, CA
2011	Consultant/Advisory Board	Boehringer Ingelheim, Ridgefield, CT
2011	Consultant/Advisory Board	Abbott, N. Chicago, IL
2011	Consultant/Advisory Board	Glaxo Smith Kline, Durham, NC
2011	Consultant/Advisory Board	Genentech, San Francisco, CA
2011	Consultant/Advisory Board	Fibrogen, San Francisco, CA
2011-2014	Consultant/DSMB	Tibotec, Cork, IR
2012	Consultant	Kadmon, New York City, NY
2013	Consultant/DSMB	Synteract, Carlsbad, CA
2013	Consultant	Applied Immunogenetics, Gaithersburg, MD
2014-2017	Consultant	MedImmune, Gaithersburg, MD
2015	Consultant/Advisory Board	Viiv/GSK, New Providence, NJ
2016	Consultant	Genfit, Loos, FR
2017	Consultant/Advisory Board	Shionogi, Florham Park, NJ
2017	Consultant/Advisory Board	Abbott Laboratories, Chicago, IL
2017,2021-2	Consultant/Advisory Board	Gilead, Foster City, CA
2017-2019	Consultant/DSMB	Watermark (for Allergan), Indianapolis, IN
2018-	Consultant/DSMB	Inovio, Philadelphia, PA
2019	Consultant	UniQure, Cambridge, MA
2020-	Consultant/DSMB	VielaBio (Horizon), Gaithersburg, MD
2020-	Consultant/Advisory Board	Theratechnologies, Montreal, CAN

### Major Administrative Leadership Positions

#### Local

1992-1994	Chief, Dept. of Clinical Investigation	Fitzsimons Army Medical Center, Denver, CO
1992-1994	Chair, Institutional Review Board	Fitzsimons Army Medical Center, Denver, CO
1994-2003	GI Fellowship Program Director	Univ. of Cincinnati, Cincinnati, OH

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

1998-2004	Director, Hepatology & Transplant Section	Univ. of Cincinnati, Cincinnati, OH
1999-2003	Director, Clinical Trials Research Office	Dept. of Medicine, Univ. of Cincinnati, Cincinnati, OH
2003-	Director/Chief, Digestive Diseases Division	Univ. of Cincinnati, Cincinnati, OH
2003-	Board of Directors	University Endoscopy Center, Montgomery, OH
2005-2007	Board of Directors	University Internal Medicine Associates, Cincinnati OH

### Committee Service

#### Local

1994-	Liver Transplant Selection Committee	University Hospital, Cincinnati, OH
1994-1997	Faculty Practice Plan Advisory Committee	UC Dept. of Medicine, Cincinnati, OH
1995	Ad Hoc Subcommittee on Laparoscopic Procedures	University Hospital, Cincinnati, OH
1995-2003	Clinical Research Committee, (Chair:1997-2003)	UC Dept. of Medicine, Cincinnati, OH
1997	Chair, Search Comm., Director Clinical Research	Health Alliance, Cincinnati, OH
1998	Space Utilization Committee	UC Dept. of Medicine, Cincinnati, OH
1998-2003	Clinical Trials Executive Committee	UC Dept. of Medicine, Cincinnati, OH
2002-2003	Institute for Clinical Research Planning Committee	Univ. of Cincinnati, Cincinnati, OH
2002-2005	University Hospital Medical Executive Committee	University Hospital, Cincinnati, OH
2005	Business Director Search Committee	UC Dept. of Medicine, Cincinnati, OH
2005-2006	Chair, Reappointment, Promotions, Tenure Comm.	UC Dept. of Medicine, Cincinnati, OH
2008-	IRB Oversight Committee Ackn	Univ. of Cincinnati, Cincinnati
2009-	Clinical and Translational Research Ctr, Scientific Advisory Committee	Univ of Cincinnati/CCHMC, Cincinnati, OH
2009-2011	Research Subcommittee on Culture Change	University Hospital, Cincinnati, OH
2011-2021	Executive and Finance Steering Committee	UC Dept. of Medicine, Cincinnati, OH
2014	CCHMC Search Committee- Pediatric GI Chair	UC Dept. of Pediatrics, Cincinnati, OH
2014	Co-Chair, Length of Stay Task Force	University Hospital, Cincinnati, OH
2017-18	Endoscopy Oversight/Planning Committee	University Hospital, Cincinnati, OH
2021-	College of Medicine Space Committee	Univ. of Cincinnati COM, Cincinnati, OH

#### National

1978-1980	Assistant Treasurer N.Y. Entomological Society
1999-2000	Hepatitis Focus Group, NIAID / AACTG
2000-2001	Liver Disease Focus Group, NIAID / AACTG
2000-2004	Chair, American Liver Foundation Subcommittee on Veterans Affairs
2000-2005	Co-Chair, Steering Committee, NCI/Multicenter Hemophilia Cohort Study
2002-2010	National Hemophilia Foundation Medical Advisory Committee
2002-2006	FDA Antiviral Advisory Committee (Chairman, 2006)
2002	Consultant to Armed Forces Hepatitis C Research Initiative, Bethesda, MD
2005-2008	NIDDK Action Plan Taskforce (HIV Section)
2005	Co-Chair, AASLD Symposium on Liver Disease in HIV-Infected Patients
2006	Chair, 1 <sup>st</sup> International Symposium on HIV and Liver Disease (NIH- funded)
2007-2008	Leader, USPHS/CDC HBV/HIV Working Group
2008	Chair, 2 <sup>nd</sup> International Symposium on HIV and Liver Disease (NIH-funded)
2010	Chair, 3 <sup>rd</sup> International Symposium on HIV and Liver Disease (NIH funded) Jackson Hole
2010-	Viral Hepatitis Advisory Board, IAS-USA

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

2010-2010 Abstract Review Committee, Conference on Retrovirus and Opportunistic Infections (CROI)  
 Moderator, Hepatitis Scientific Section, Conf. on Retroviruses and Opportunistic Infections (CROI), San Francisco

2012 Discussant/Moderator, Conf. on Retroviruses and Opportunistic Infections (CROI), Seattle

2012 Chair, 4th International Conference on HIV and Liver Disease (NIH funded), Jackson Hole

2012 Advisory Board, NIAID, Women's Interagency HIV Study (WIHS)

2014 Chair, 5<sup>th</sup> Biennial HIV and Liver Disease Forum 2014, Moran, WY

2015 Moderator, Keefe Symposium, DDW, Washington, DC

2015 Moderator/Abstract Reviewer, Collaborative Forum on HIV and Hepatitis National Meeting, Washington, DC

2015 Co-Chair, IAS-USA Management of Hepatitis C in the New Era, Chicago

2016 Chair, 6<sup>th</sup> Biennial HIV and Liver Disease Symposium, Moran, WY

2016 Moderator, DDW (4 sessions), San Diego

2016 Moderator, CROI, Boston

2017 Moderator, HepDart, Kona, HI

2017 Panelist, IDSA Annual Meeting, San Diego, CA

2018 Moderator, DDW (3 sessions), Washington, DC

2019 Moderator, DDW (3 sessions), San Diego, CA

2021 Chair, 7<sup>th</sup> Biennial HIV and Liver Disease Conference, Jackson Hole, WY

#### International

2018	Organizing Committee, 14 <sup>th</sup> European Coinfection Workshop	Seville, Spain
2017	Organizing Committee, 13 <sup>th</sup> European Coinfection Workshop	Lisbon, Portugal
2016	Organizing Committee, 12 <sup>th</sup> European Coinfection Workshop	Berlin, Germany
2015	Organizing Committee, 11 <sup>th</sup> European Coinfection Workshop	London, UK
2014	Organizing Committee, 10 <sup>th</sup> European Coinfection Workshop	Paris, France
2013	Co-Chair, 9 <sup>th</sup> European Workshop on HIV and Coinfections	Rome, Italy
2012	Organizing Committee, 8 <sup>th</sup> European Workshop on HIV & Coinfection	Madrid, Spain
2011	Organizing Committee, 7 <sup>th</sup> European Workshop on HIV & Coinfection	Milan, Italy
2010	Organizing Committee Member, 6 <sup>th</sup> International Workshop on HIV & Coinfections	Tel Aviv, Israel
2009	Co-Chair, 5 <sup>th</sup> International Workshop on HIV & Coinfection	Lisbon, Portugal
2008	Organizing Committee, 4 <sup>th</sup> Int. Workshop on HIV and Coinfections	Madrid, Spain

#### Professional Societies

1978-	American Society for Microbiology	Member
1988-	American College of Physicians (ACP)	Member
1995-		Fellow
1989-	American College of Gastroenterology (ACG)	Member
1996-1997		Education Sub-Committee
1996-		Fellow
1989-	American Gastroenterological Association (AGA)	Member

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

	1998-2001	Manpower & Training Committee
	2001-2004	Comm on Publications and Informatics
	2004-2007	AGA Ethics Committee
	2014-2017	Vice Chair, Liver & Biliary Section
	2018	AGA Nominating Committee
	2017-2019	Chair, Liver & Biliary Section
	2020-2021	Chair, Liver/Biliary Nominating Comm
	2017-	Fellow
1991	American Association for the Study of Liver Disease	Member
	1995-1998	Clinical Research Committee
	1999	Co-Chair, Clinical Research Symposium
	2003-2005	Membership Committee
	2009	Co-Moderator, HCV Viral Clearance
	2008	NIH Liaison Committee
	2011	Co-Moderator Workshop Acute Hepatitis
	2012	Moderator, HCV Mol Virology Mtg
	2013	Moderator, Emerging Infections Sym.
	2013-2015	HCV Consensus Guidelines Committee
	2016-	Fellow of the AASLD
	2021-2022	DDW Working Group
2005-	European Association for the Study of Liver	Member
2014-	New York Academy of Science	Member
2015-	American Association for the Advancement of Science	Member
2018-	Infectious Disease Society of America	Member

### **Grant Review Activities**

2001	Special Emphasis Panel ZDK1 GRB-6(M3)	NIH
2001-2003	Liver Disease Subcommittee, NIAID / AACTG	NIH
2004-2006	Hepatitis Research Advisory Committee (HEPRAC), NIAID/AACTG	NIH
2004	GCRC Study Section	NIH
2005	NIH/NIAID Study Section for AIDS Cooperative Groups	NIH
2007-2008	Vice-Chair, NIAID/ACTG Hepatitis Committee/SASC Member	NIH
2008	Chair, NIDDK Study Section (ZDK1 GRB-N O3)	NIH
2009-2011	Chair, NIAID/ACTG Hepatitis Committee/SASC Member	NIH
2009	NIAID Study Section (ZAI1-ELB-M-S2)	NIH
2011	NIAID Study Section (ZAI1-NLE-M-M2)	NIH
2013	NIAID Study Section (ZAI1-MM-M S1)	NIH
2014	NIAID Study Section (ZAI1 TT-M (J1) 1)	NIH
2015-	NIAID/ACTG TSG Hepatitis Steering Committee	NIH
2016	NIAID Study Section (ZAI1-AWA-M-S1)	NIH
2017	Chair, NIAID Study Section (ZAI1 RCU-M (S1))	NIH
2018	NIAID Study Section (ZHL1 CSR-B (01)1)	NIH
2019	NIAID Study Section (ZA1-EC-D-S1)	NIH
2020	NIAID Study Section (ZAI1 LBD-D (S1)	NIH

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

## Editorial Activities

### **Ad hoc Reviewer**

*AIDS*

*Alimentary Pharmacology & Therapeutics*

*American Journal of Gastroenterology*

*Annals of Internal Medicine*

*Blood*

*Clinical Infectious Diseases*

*Contagion*

*Digestive Diseases and Sciences*

*Gastroenterology*

*Journal of AIDS*

*Journal of the American Medical Association*

*Journal of Infectious Diseases*

*Hepatology*

*Lancet*

*Minerva Gastroenterologica*

*New England Journal of Medicine*

*PLoS One*

*Journal of Clinical Investigation*

### **Other Editorial Roles**

1997-2004	Member Editorial Board	<i>American Journal of Gastroenterology</i>
2005-2006	Member Editorial Board	<i>Contagion</i>
2005	Member Editorial Board	<i>Current Hepatitis Reports</i>
2006-2009	Member Editorial Board	<i>Hepatology</i>
2007-	Member Editorial Board	<i>Minerva Gastroenterologica</i>
2011	Member Editorial Board	<i>Annals of the Forum for Collaborative HIV Research</i>
2017-	Member Editorial Board	<i>Pathogens &amp; Immunity</i>

## Honors and Prizes

1976	Alpha Zeta (National Agricultural Honor Society)	Rutgers University
1976-80	Busch Pre-doctoral Fellow/Waksman Institute for Microbiology	Rutgers University
1979	Sigma Xi (National Research Honor Society)	Rutgers University
1986	Donald Glew Medical Student Research Award	George Washington SOM
1989	U.S. Army Achievement Medal for Research Activities	U.S. Army Medical Corps
1989	William Beaumont Award for Clinical Research/Gastroenterology	U.S. Army Medical Corps
1994	Army Meritorious Service Medal	U.S. Army Medical Corps
2002	Endowed Chair in Medicine (Gould Chair)	Univ. of Cincinnati
2005	Who's Who in America 59 <sup>th</sup> Edition, 2005	Marquis Who's Who
2005-	Best Doctors in America	Cincy Magazine
2008	Alpha Omega Alpha (AOA)	Univ. of Cincinnati

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

2012	Tim Gill Distinguished Lecturer	Univ. of Colorado SOM
2014	Karl Maramorosch Distinguished Lecturer	Rutgers University
2015	Caroll Leevy Award for Hepatology & Transplantation	New Jersey COM- Rutgers
2018-	Who's Who in the World	Marquis Who's Who
2021	Distinguished Research Professor in a STEM Discipline	Univ. of Cincinnati
2022	Liver/Biliary Research Mentor of Year Award	AGA Institute

## **Report of Funded and Unfunded Projects**

### **Past**

1996-1998	Evaluation and Characterization of HCV RNA: Alcoholics vs. Non-Alcoholics Veteran's Administration Research Advisory Group PI Evaluate the effect of alcohol on HCV RNA quasispecies variability.
1997-2000	HCV Viral Variability in HIV Co-Infected Hemophiliacs NCI/Multicenter Hemophilia Cohort Study Grant PI Evaluation of HCV RNA quasispecies variability in HIV-infected and uninfected men
1999-2001	Health Utilities in Hepatitis C Infected Patients RO3 HS10366-01 PI Develop patient derived health utilities in chronic HCV infected persons.
1999-2001	Prevalence and Dynamics of HCV in HIV Co-Infected Patients NIAID/ACTG PI Evaluation of HCV in the ACTG cohort
2001-2006	HCV Genomic Variability in HIV Infected Hemophiliacs NIAID RO1 AI49508 PI Determine is quasispecies emergence is associated with liver disease progression in hemophiliacs with HCV or HCV/HIV coinfection
2000-2013	AIDS Clinical Trials Unit/Cincinnati Site NIAID/ACTG UO1 AI69513 Co-Investigator (PI J. Feinberg/C Fichtenbaum) Performance of clinical trials related to HIV disease
2003-2008	Solid Organ Transplantation in HIV: A Multi-site Study NIAID UO1 AI052748 Co-Investigator/Site PI (PI P Stock/M Roland) Observational cohort study of liver transplantation and kidney transplantation in HIV-infected persons.
2003-2008	Suppressive Long Term Hepatitis C Antiviral Management of Coinfected Patients (SLAM-C/A5178)

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

NIAID/ACTG UO1 AI38858

PI

Evaluation of paired liver biopsies in patients receiving long-term pegylated interferon for chronic HCV/HIV coinfection.

2005- 2016

Mentorship in Liver Disease

K24 DK07528

PI

Provide mentorship and guidance to young investigators in liver research.

2006-2008

Extrahepatic Replication and Viral Evolution of HCV during HCV/HIV Co-infection

R21 DA022148

Co-Investigator (PI J Blackard)

Evaluation of evolutionary dynamics of HCV and HCV/HIV coinfecting patients including examination of viral sequence differences in protected or discrete sites.

2006-2008

Towards Understanding the Morbidity of HEV Infection

R21 AI067868

Co-Investigator (PI MT Shata)

Hepatitis E virus epidemiology in Nile River Valley

2006-2011

Antiretroviral Therapy and the Hepatitis C Virus

NIAID RO1 AI065256

PI

Characterize early and late HCV and HIV viral kinetics following initiation of ART

2007-2010

AIDS Clinical Trials Network Leadership

NIH/NIAID UO1 AI068636

PI

Provide support of administrative leadership for the Chair/Vice-Chair of the ACTG Hepatitis Committee

2008

Antiretroviral Therapy and HCV/HIV

M01 RR008084

PI

Evaluate liver injury and hepatic fibrosis during initiation of cART in HIV-infected persons

2009-2012

Clinical Relevance of GB Virus C Interaction with HIV and Hepatitis C Virus in High risk Women

NIAID R21 AI081564

Co-Investigator (PI J Blackard)

Determine the role of GBV-C on HIV disease progression in women.

2010-2011

Pilot Study-HEV in HIV-Infected Liver Transplant Recipients

NIAID UO1 AI052748 (PI P Stock/M Roland)

PI

Determine prevalence and incidence of HEV in the HIV Solid Organ Transplant Candidates

2011-2013

Effect of CCR5 Blockade on Liver Disease Progression in HIV Patients

NIAID Bench-to-Bedside Grant

Extramural PI (Intramural PI S Kottlilil)

Examine associations of hepatic fibrosis mediated through the CCR5 receptor

Curriculum Vitae: Kenneth E. Sherman, MD, PhD



- 2011-2013 Exploring the Role of Gut-Associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients  
Merck IISP 38879  
Co-Investigator (PI MT Shata)
- 2011-2013 The Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States  
Merck IISP 39510  
PI  
Develop a decision analytic model that can be used to make assessments of effectiveness of HCV screening/treatment in various HCV population groups
- 2011-2014 A Prospective, Phase II, Open-Label Study of Boceprevir, Pegylated Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects (BIRTH)  
NIAID/ACTG UM1 AI068636 (PI D Kuritzkes)  
Co-Chair  
Develop and co-lead ACTG 5294 Multicenter trial to determine efficacy of protease-inhibitor based regimen in HCV cure in HCV/HIV coinfectd patients.
- 2012-2015 Evaluating the role of the immune response in the emergence of HCV NS3 resistance mutations during protease inhibitor therapy  
Merck Investigator Initiated Study Investigator IISP 40458  
Co-Investigator (PI MT Shata)  
Examine the role of HLA binding and the T cell repertoire in the emergence of protease inhibitor mutations that may lead to loss of immunological control of resistant HCV
- 2012-2015 Viral Kinetic Models of HCV Clearance in Hemophiliacs Treated with Telaprevir  
R34 HL109334  
PI  
To develop a kinetic model of HCV viral clearance in hemophiliacs with HCV infection who are treated with a protease inhibitor for HCV.
- 2013-2015 The Hemophilia Center of Western Pennsylvania Hemophilia Liver Transplantation Observational Study (HOTS)  
HRSA/PRO12060248  
Co-Investigator (PI M Ragni)  
Establish a hemophilia treatment center network and determine mechanisms underlying outcomes of hemophilia patients as related to liver transplantation.
- 2013-2019 Genotypic and Phenotypic Characterization of the HCV Polymerase (NS5B)  
NIGMS RO1 GM105414  
Co-Investigator (PI J Blackard)  
Comprehensive assessment of the genotypic, phenotypic and biochemical variability of the HCV RNA-dependent RNA polymerase in patient with HCV or HCV/HIV
- 2014-2016 Hepatitis C Analysis on Banked Samples  
Gilead  
Co-Investigator  
Estimate the prevalence of HCV in the Emergency Department population.
- 2014-2016 Immune Checkpoint Markers in Patients with Chronic Liver Disease

MedImmune

PI

Analyze the activity and functionality of immune cell subsets presents in patients with liver disease and healthy controls.

2015-2016

Ultra-deep Sequencing of NS5A Resistance Variants in HCV/HIV Coinfected Patients

Merck Investigator Initiated Study

PI

Characterize the frequency of NS5A RAVs in HCV/HIV coinfection patients and HCV monoinfected controls.

2017-2018

Zika Virus Replication in Hepatocytes

Univ. of Cincinnati Dept. of Medicine Distinguished Investigator Award

PI

Determine replication potential of hepatocyte cell lines for Zika virus infection and evaluate and optimize serologic assays for Zika infection

2018

Cost-Effectiveness of Screening for Chronic HCV Infection

CDC Foundation

PI

Develop a Markov model to determine if universal HCV screening would be cost-effective in the U.S.

2017-2019

Timing of Treatment for Chronic Hepatitis C Infection in Patients with End Stage Renal Disease Awaiting Transplantation

Merck Investigator Initiated Study

PI

The goal of this project is to use mathematical modeling methods to determine the optimal strategy for timing HCV treatment relative to renal transplantation in patients with ESRD on dialysis

## **Current/Recent**

2021-2023

Biomarkers of Replication and Injury in HBV/HIV

R21AI165171

PI

Evaluate role of advanced biomarkers including pre-genomic RNA and quantitative HBsAg in predicting disease and response outcomes in persons living with HIV infection

2006-2023

Liver Disease and HIV

R13AI071925

PI

Organize conference focused on research and clinical issues related to development and progression of liver disease in persons living with HIV

2013-2021

Genotypic and phenotypic characterization of the HCV polymerase (NS5B)

R01GM105414

Curriculum Vitae: Kenneth E. Sherman, MD, PhD

Co-Investigator (PI J Blackard)  
Genotypic and phenotypic characterization of the HCV polymerase (NS5B)

- 2013-2025 ACTG/Case Clinical Trials Unit/Cincinnati Clinical Research Site  
UM1AI069501 NIAID/ACTG Clinical Trials Unit/Cincinnati Site  
Co-Investigator (PI M Lederman, Case Western Reserve)  
Maintain AID Clinical Trials Unit
- 2015-2021 Hepatitis E in HIV-Infected Patients  
R01DK108362  
PI  
Determine the clinical significance of HEV infection in HIV-infected patients
- 2015-2021 Cohort Studies of HIV/AIDS and Substance Abuse in Miami  
U01DA036929  
Co-Investigator (PI M Baum)  
Develop a longitudinal cohort of cocaine users with HIV and evaluate the impact of cocaine on development of hepatic fibrosis.
- 2006-2021 Antiretroviral Therapy and Hepatic Injury (formerly Antiretroviral Therapy & the HIV Virus)  
R01AI065256  
PI  
The goal of this project is to study a chemokine receptor, CCR5, and its role in modulating hepatic fibrosis.
- 2016-2021 The Prioritize Study: A pragmatic, randomized study of oral regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders  
PCORI  
Co-Investigator (PI D Nelson)
- 2020-2021 SARS-CoV-2 and the Liver  
University of Cincinnati Pilot Award in COVID-19 Related Research  
PI  
Evaluate replication potential of hepatocytes for SARS-CoV-2 and develop ELISPOT assays to assess T-cell responses in subjects with liver disease

### **Report of Local Teaching and Training**

#### **University of Cincinnati College of Medicine**

1994-2015 Viral Hepatitis in ICP II (2<sup>nd</sup> year medical students) 1 hour session/year

2016-2019	Alcoholic/Non-Alcoholic Fatty Liver (2 <sup>nd</sup> year medical students)	1 hour session/year
2017-2018	Viral Hepatitis (Masters Public Health Infectious Disease Course)	3 hour session/year
1994-	Professor's Rounds -Acute & Chronic Hepatitis (3 <sup>rd</sup> Year Medical)	6 hours/year

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

1995	Medical Grand Rounds, Lecturer, "Hepatitis C" 50 medical students, residents and fellows	Univ. of Cincinnati
1995-2018	Fellows Summer Lecture Series, Epidemiology and Biostatistics GI Fellows, Rotating Residents (10)	Univ. of Cincinnati
1998	Medical Grand Rounds, Lecturer, "Evaluation of Liver Tests" 50 medical students, residents and fellows	Univ. of Cincinnati
2004	Clinicopathologic Case Conference Discussant, "Fever in an HIV Patient" 50 medical students, residents and fellows	Univ. of Cincinnati
2005	Medical Grand Round, Lecturer, "HCV- The Silent Epidemic" 50 medical students, residents and fellows	Univ. of Cincinnati
2015	Medical Grand Rounds, Lecturer, "HCV For The Internist" 50 medical students, residents and fellows	Univ. of Cincinnati
2016	Medical Grand Rounds, Lecturer, "Hepatitis B: The Undiscovered Country" 50 medical students, residents and fellows	Univ. of Cincinnati
2016	Clinical Concepts, GI Fellows (10), "Treatment of Hepatitis B"	Univ. of Cincinnati
2017	Clinical Concepts, GI Fellows (10), "HCV/HIV Coinfection"	Univ. of Cincinnati
2018	Clinical Concepts, GI Fellows (10), "NAFLD/NASH"	Univ of Cincinnati
2019	Clinical Concepts, GI Fellows (10), "Hepatitis A and E"	Univ. of Cincinnati
2020	Medical Grand Rounds, Lecturer, "SARS CoV-2 and the Digestive Tract" 50 Medical Students, Residents, Fellows	Univ. of Cincinnati
2020	Fellow Summer Lecture Series, Epidemiology Principles GI Fellows, Rotating Residents (12)	Univ. of Cincinnati

Clinical Supervisory and Training Responsibilities

1994-2019	Attending physician, General Medicine Services/GI-Liver Service (Residents/Med Students) 4 weeks/year
-----------	--

- 1994-2000 Veteran's Administration Hospital Liver Clinic (Residents, GI Fellows)  
1 ½ day session/week
- 1994-2012 Liver Clinic at University Hospital (Medical Residents, GI Fellows, Medical Students)  
1 ½ day session/week
- 1994- Liver Consult Service Attending (GI Fellows, Medical Residents, Medical Students)  
2-10 weeks/year

Laboratory and Other Research Supervisory and Training Responsibilities

University of Cincinnati College of Medicine

2003-2006	PhD Dissertation Advisory Committee, Kelly Flory	10 hours/year
2003-2008	MD/PhD Candidate Advisor, Anand Pathak	10 hours/year
2003-2006	PhD Candidate Advisor, Norah Shire	80 hours/year
2007-2011	PhD Dissertation Advisory Committee, Christina Martin	20 hours/year
2012-2015	PhD Dissertation Advisory Committee, Elanor Powell	20 hours/year
2013-2020	MD/PhD (MSTP) Promotion Board, Univ. of Cincinnati COM	10 hours/year
2016-	Senior Mentor, MD/PhD Candidate, Phillip Witcher	10 hours/year
2021-present	PhD Dissertation Advisory Committee, Hope Gauthier	20 hours/year

Formally Supervised Trainees and Faculty

- 1991-1994 Dirk Davis, MD Gastroenterologist, Northern Utah Gastroenterology  
As a fellow Dr. Davis participated and co-authored a clinical trial published in *Hepatology*
- 1992-1994 Robert Sudduth, MD, Gastroenterologist, The Doctors Clinic  
As a fellow Dr. Sudduth published a first-author manuscript in *Gastrointestinal Endoscopy*
- 1992-1994 Scot Lewey, DO, Clinical Professor of Medicine, Kansas City Univ. of Medicine and Front Range Gastroenterology  
As a fellow, Dr. Lewey co-authored papers published in *American Journal of Gastroenterology and Hepatology*
- 1994-1996 Spencer Root, MD, Gastroenterologist, The Doctors Clinic  
As a fellow Dr. Root published a first-author paper in *Journal of Clinical Gastroenterology*
- 1995-1996 Raj Jain, MD, Rocky Mountain Gastroenterology  
As a fellow, Dr. Jain published a first-author paper in *Seminars in Liver Disease*
- 1997-1998 Jaime Aranda-Michel, MD, Oregon Health Sciences University/Adventist Health  
As a fellow Dr. Aranda-Michel first-authored a manuscript published in *Gastroenterologist* and co-authored an article in *Liver Transplantation & Surgery*
- 2002-2005 Hongxing Qin, MD, PhD, Deceased  
As a post-doctoral fellow Dr. Qin published a first-author paper in *Blood*
- 2002-2005 Joseph Mrus, MD, Executive Medical Director, Viiv Healthcare

- As a junior faculty Dr. Mrus published a first author paper in *Medical Care*
- 2003-2006 Chris Duncan, MD Gastroenterologist, CHI Franciscan Health  
Dr. Duncan worked on clinical research projects of HCV and HBV, learning GCP
- 2003-2008 Norah Shire, PhD Medical Director, Astra-Zeneca  
As a PhD candidate and then junior faculty in my research group Dr. Shire had multiple published manuscripts including first-author publications in *Hepatology, Vaccine, Clinical Infectious Diseases, JAIDS, and Journal of Viral Hepatitis*
- 2004-2006 Sooyun Chun, MD Gastroenterologist, The Corvallis Clinic  
As a fellow, Dr. Chung was published a first-author manuscript in *Clinics in Liver Disease*
- 2004-2011 Nyingi Kemmer, MD Professor, Univ. of South Florida  
As junior faculty, Dr. Kemmer published first-author manuscripts in *Nature Clinical Practice Gastroenterology/Hepatology, Digestive Diseases and Sciences and Journal of Viral Hepatitis*
- 2005 Rachel Habbert, PhD Candidate, Univ. of California- Berkeley  
As an undergraduate summer student worked on clinical database management and virological lab methods
- 2005-2007 Muslum Atiq, MD Assistant Professor, Sanford University  
As a resident working in the lab, Dr. Atiq first-authored a manuscript published in *Emerging Infectious Diseases*
- 2005-2010 Jason Blackard, PhD Associate Professor, Univ. of Cincinnati  
As a junior faculty Dr. Blackard had first-authorship on manuscripts published in *Hepatology, Journal of Infectious Diseases* and numerous other journals
- 2007-2010 Phillippe Zamor, MD, Assistant Professor, Carolinas Health System/Wake Forest  
As a fellow, Dr. Zamor co-authored a manuscript published in *Haemophilia*
- 2007-2011 Christina Martin, PhD Post-doctoral fellow, Cincinnati Children's Medical Center  
As a graduate student, Dr. Martin had first-author and co-author publications in *Journal of Viral Hepatitis, Cytokine and Journal of Clinical Microbiology*
- 2007-2011 Tiffany Kaiser, PharmD Associate Professor of Medicine, Univ. of Cincinnati  
As junior faculty, Dr. Kaiser published a co-authored manuscript in *Clinical Infectious Diseases*
- 2008-2010 Paul Schmeltzer, MD Assistant Professor, Carolinas Health System/Wake Forest  
As a fellow, Dr. Schmeltzer was the first-author on a manuscript published in *Digestive Diseases and Sciences*
- 2008-2010 Sara Rashkin, PhD Post-doctoral fellow, Univ. of California, San Francisco  
As an undergraduate student she was the first-author of a manuscript published in *Journal of Viral Hepatitis*

- 2008-2012 Peter Dryer, MD Gastroenterologist, TriHealth  
As a resident and fellow, Dr. Dryer published one first-author and one co-author manuscript in *Journal of Antimicrobial Chemotherapy and Journal of Clinical Microbiology*
- 2008-2012 Amy DiChiara, MD Gastroenterologist, St. Elizabeth's Health System  
As a fellow, Dr. DiChiara published a first-author manuscript in *Minerva Gastroenterologica*
- 2010-2013 Waseem Butt, MD Gastroenterologist, Geisinger Clinic  
As a resident and Master's student, Dr. Butt worked on development of a multi-center study of acute hepatitis C in the ACTG
- 2009-2013 Maria Hernandez, MD Assistant Professor, Univ. of Miami  
As a fellow, Dr. Hernandez published a first-author manuscript in *Current Opinions in HIV and AIDS*
- 2010-2013 Ming Valerie Lin, MD Hepatologist, Lahey Clinic  
As a fellow, Dr. Lin was first-author in a manuscript published in *Haemophilia*
- 2010-2015 Michael Schoech, MD Assistant Professor of Medicine, Univ. of Cincinnati  
As a fellow Dr. Schoech participated in research leading to co-authorship of a manuscript published in *Hepatology*
- 2011-2015 Syed Hussain, MD Hepatologist, Aurora Healthcare  
As a fellow, Dr. Hussain first-authored a Cases on the Web (COW) for the International Aids Society- USA on liver transplantation in the setting of HIV
- 2011-2015 Vidhya Kunnathur, MD Associate Professor, Univ. of Cincinnati  
As a fellow, Dr. Kunnathur co-authored a manuscript published in *Clinical Infectious Diseases*
- 2011-2016 Enass Abdel-Hameed, MD, PhD Research Associate, Univ. of Cincinnati  
As a post-doctoral fellow, Dr. Abdel-Hameed published first-author manuscripts in *JAIDS, Digestive Diseases and Sciences and Viral Immunology*
- 2012-2015 Helal Hetta, MD, PhD Postdoctoral fellow, Univ. of Cincinnati  
As a PhD candidate at Assuit Univ in Egypt, working in our laboratory, Dr. Hetta published first author manuscripts in *Journal of Gastroenterology and Hepatology, and Journal of Medical Microbiology*
- 2013-2015 Minesh Mehta, MD Gastroenterology Fellow, Univ. of Louisville  
As a resident, Dr. Mehta published a first-author manuscript published in *Archives of Virology*
- 2013-2016 Sanam Razeghi, MD Assistant Professor, Pennsylvania State Univ. Medical Center  
As a fellow, Dr. Razeghi co-authored a paper published in *Virus Research*

- 2014-present Khurram Bari, MD Associate Professor, Univ. of Cincinnati  
As junior faculty, Dr. Bari published a first-author manuscript in *Hepatology*
- 2016-2018 Liza Murrison, PhD Assistant Professor, Univ. of Cincinnati  
As junior faculty, Dr. Murrison published a first-author manuscript in *Gastroenterology & Hepatology*
- 2017-19 Andrea Portocarrero, MD GI Fellow, University of Cincinnati  
As a resident, Dr. Portocarrero has been working on diagnosis of zoonotic hepatitis E infection and HCV in pregnancy
- 2018-2020 Aradhna Seth, MD Hepatologist/faculty Univ. of Western Washington  
As a fellow Dr. Seth published a first-author manuscript on Fatty Liver in HIV in *Topics in Antiviral Medicine* and a first-author manuscript on HEV in *Chronic Liver Disease*
- 2019-present Priya Farooq, MD Assistant Professor, Univ. of Rochester  
As a fellow Dr. Farooq published a first author article on vaccination in HBV/HIV infected persons in *Current HIV/AIDS Reports*
- 2019-present Yeshika Sharma, MD Assistant Professor, University of Cincinnati  
As a fellow Dr. Sharma completed a book chapter on hepatitis viruses and pregnancy
- 2020-present Arun Jose, MD Assistant Professor, Univ. of Cincinnati  
As a junior faculty member, Dr. Jose was first author on a paper in *Liver Transplantation*
- 2021-present Alexandra Willauer, MD Internal Medicine Resident  
Dr. Willauer is working on development of liver organoids
- 2022 Debra Yen, MD Gastroenterology Fellow  
Dr. Yen is working on a manuscript related to hepatic fibrosis in PLWH

#### Invited Presentations and Courses

#### **Regional, National, and International Invited Presentations and Courses**

#### **Regional (within 100 miles of Cincinnati, OH)**

- 1995 Invited Speaker: "Hepatitis C"  
Middletown Regional Hospital Grand Rounds, Middletown, OH
- 1995 Invited Speaker: "Hepatitis C Treatment"  
Veterans Administration Hospital, Dayton, OH
- 1996 Invited Speaker: "Chronic hepatitis and the role of transplantation"  
Veterans Administration Hospital, Chillicothe, OH
- 1998 Invited Speaker: "Hepatitis in HIV-infected patients"  
Cincinnati Infectious Disease Annual Conference, Cincinnati, OH
- 1999 Invited Speaker: "Diagnosis and management of hepatitis C"



Appalachian Regional Hospital System, Hazard, KY

- 2000 Invited Speaker: "Evaluation and management of hepatitis C disease"  
Ohio American College of Physicians Annual Scientific Meeting, Cincinnati, OH
- 2002 Invited Speaker: "HCV/HIV Coinfection"  
Cincinnati Retroviral Infectious Disease Update, Cincinnati, OH
- 2002 Invited Speaker: "HCV Treatment"  
Hepatitis C Public Forum, Cincinnati, OH
- 2003 Invited Speaker: "Viral Hepatitis"  
University of Cincinnati Mini Medical College, Cincinnati, OH
- 2003 Invited Speaker: "A New Approach: Evaluating HCV from the ID Perspective"  
Dayton Infectious Disease Society, Dayton, OH
- 2008 Invited Speaker: "Hepatitis C Treatment"  
University of Cincinnati Liver Forum, Cincinnati, OH
- 2012 Invited Speaker: "Current insights in hepatic encephalopathy"  
Chronic Liver Disease Foundation Dinner Meeting, Cincinnati, OH
- 2016 Invited Speaker: "Current and future options for PBC, NASH and hepatic encephalopathy"  
Chronic Liver Disease Foundation Dinner Meeting, Cincinnati, OH
- 2017 Invited Speaker: "HCV Advances for ID"  
Chronic Liver Disease Foundation Dinner Meeting, Cincinnati, OH
- 2017 Invited Speaker: "Hepatitis C Treatment and Management"  
Veterans Administration Hospital, Chillicothe, OH
- 2018 Invited Speaker: "Update on PBC"  
Chronic Liver Disease Foundation Dinner Meeting, Cincinnati, OH
- 2019 Invited Speaker: "PBC Diagnosis and Treatment"  
Chronic Liver Disease Foundation Dinner Meeting, WestChester, OH
- 2019 Invited Speaker: "HCV Screening and Treatment"  
UC Liver Forum, Cincinnati, OH
- 2019 Invited Speaker: "Viral Hepatitis Update"  
UC AASLD Review, Cincinnati, OH
- 2021 Invited Speaker: "Viral Hepatitis and Related Topics"  
SC Liver Consortium, Cincinnati, OH

## **National**

- 1993 Invited Speaker: "Hepatitis C Quasispecies Variability"  
NIH Liver Unit, Bethesda, MD
- 1993 Invited Speaker: "Hepatitis C Diagnosis and Treatment"  
Cleveland Clinic, Cleveland, OH
- 1994- Invited Speaker: "Evaluation of Liver Tests"  
2009 Annual Armed Forces Institute of Pathology Hepatopathology Course, Vail, CO & Washington, DC
- 1994 Invited Speaker: "Diagnosis and Treatment of Hepatitis C"  
Madigan Army Medical Center, Tacoma, WA
- 1995 Invited Speaker: "Hepatitis C Treatment"  
Grand Rounds, Wayne State University Medical Center, Detroit, MI
- 1996 Invited Speaker: "Hepatitis C and HIV"  
Hawaiian Gut Club, Honolulu, HI
- 1996 Invited Speaker: "Hepatitis C Treatment and Management"  
Kaiser Permanente, Honolulu, HI
- 1996 Invited Speaker: "Hepatitis C Treatment"  
Dearborn Hospital Medical Grand Rounds, Dearborn, MI
- 1997 Invited Speaker: "Chronic hepatitis C for primary care providers"  
Dinner program, sponsored by Cleveland Clinic foundation, Youngstown, OH
- 1997 Invited Speaker: "Hepatitis C Heterogeneity"  
Cleveland Clinic GI Research Conference, Cleveland, OH
- 1998 Invited Lecturer: "Interpretation of Liver Tests"  
Grand Rounds, University of Alabama-Montgomery, Montgomery, AL
- 1998 Invited Speaker: "Laboratory evaluation of hepatitis viruses"  
National Hemophilia Foundation Association, Philadelphia, PA
- 1998 Invited Speaker: "Hepatitis C diagnosis and management"  
Grand Rounds, Poudre Valley Hospital, Ft. Collins, CO
- 1998 Invited Lecturer: "Current perspectives on the management of hepatitis C"  
Grand Rounds, George Washington University SOM, Washington, DC
- 1998 Invited Speaker: "Treatment of hepatitis C"  
25<sup>th</sup> Annual meeting of the Aids Clinical Trials Group, Washington, DC

- 1998 Invited Speaker: "Genotype change in hemophiliacs"  
Hemophilia Multicenter Cohort Study Annual Meeting, Washington, DC
- 1999 Invited Speaker: "Update on hepatitis C management"  
Uniformed Family Physicians Association Annual meeting, Las Vegas, NV
- 1999 Invited Lecturer: "Hepatitis C Heterogeneity"  
Infectious Disease Research Conference, Univ. of Colorado HSC, Denver, CO
- 1999 Invited Speaker: "Update on management of hepatitis C"  
Federal Corrections Health Conference, Pueblo, CO
- 1999 Invited Speaker: "Importance of HCV in HIV-infected Patients"  
AIDS Clinical Trials Group Leadership Retreat, San Diego, CA
- 1999 Invited Speaker: "Hepatitis C in HIV-infected Patients"  
Ryan White National Conference, Tucson, AZ
- 1999 Invited Speaker: "The Co-infected Patient"  
ANAC-Metro HIV Conference, Atlanta, GA
- 1999 Invited Speaker: "Hepatitis in HIV-infected Patients"  
Emory University GI Division Research Dinner Conference, Atlanta, GA
- 1999 Invited Speaker: "Update on the treatment of hepatitis C"  
Hawaiian Gut Club, Honolulu, HI
- 1999 Invited Speaker: "Hepatitis C Diagnosis and Treatment"  
Grand Rounds, Tripler Army Medical Center, Honolulu, HI
- 1999 Invited Speaker: "HCV/HIV Coinfection"  
AASLD Annual Meeting Meet-the-Professor, Dallas, TX
- 1999 Invited Lecturer: "Evaluation of Abnormal Liver Tests"  
Grand Rounds, University of Texas Medical Center, Houston, TX
- 2000 Invited Lecturer: "Hepatitis C Diagnosis and Treatment"  
Grand Rounds, Memorial Hospital Medical Center, Southbend, IN
- 2000 Invited Speaker: "Treatment of HCV in the HIV-infected Patient"  
Rocky Mountain Pus Club, Jackson, WY
- 2001 Invited Speaker: "Hepatitis C Diagnosis and Management"  
University of Louisville Advances in Hepatology for 2001 Conference, Louisville, KY
- 2001 Invited Speaker: "HCV/HIV Coinfection"  
University of Hawaii AIDS Consortium Annual Meeting, Honolulu, HI
- 2001 Invited Speaker: "Treatment of hepatitis C"

Beaumont Medical Center Gastroenterology Research Conference, Detroit, MI

- 2001 Invited Lecturer: “Hepatitis C in HIV”  
Infectious Disease Division Research Conference, Indiana University, Indianapolis, IN
- 2001 Invited Lecturer: “Hepatitis C Management”  
Grand Rounds, Northwest Ohio College of Medicine, Toledo, OH
- 2001 State of the Art Lecture: “Hepatitis C in HIV”  
Conference on Retroviruses and Opportunistic Infections, Chicago, IL
- 2001 Invited Lecturer: “Hepatitis and HIV Coinfections”  
Grand Rounds, Ohio State University Medical Center, Columbus, OH
- 2001 Meet-the-Expert Speaker: “HCV/HIV Coinfection”  
AASLD Annual Meeting
- 2002 Invited Speaker, “Hepatitis C and HIV”  
Annual Greater Washington Infectious Disease Update Conference, Washington, DC
- 2002 Invited Speaker, “HCV/HIV Coinfection”  
Guidelines Committee for the Treatment of Opportunistic Infections in Persons with HIV,  
Washington, DC
- 2002 Invited Speaker, “Hepatitis C and HIV”  
Washington University Annual Retrovirus Update Course, St. Louis, MO
- 2002 Invited Speaker, “Hepatitis C Treatment”  
FAMOHIO Annual Meeting, Columbus, OH
- 2002 Invited Lecturer, “Hepatitis C Management and Treatment”  
Infectious Diseases Grand Rounds, Henry Ford Medical Center, Detroit, MI
- 2003 Invited Speaker: “Importance of HCV in HIV-infected People”  
CPCRA Second New Science Retreat, Miami, FL
- 2003 Invited Speaker: “Hepatitis C Quasispecies Variation”  
Multicenter Hemophilia Cohort Study Annual Retreat, Washington, DC
- 2003 Invited Speaker: “Hepatitis C- New Treatment Options”  
Emerging Advances in HCV Therapy Symposium, Univ. of Kentucky, Lexington, KY
- 2003 Invited Speaker: “Treatment of Hepatitis C”  
43<sup>rd</sup> Annual ICAAC Educational Symposium
- 2003 Invited Speaker: “HBV and HCV in HIV-Infected Patients”  
AMFAR (American Federation of AIDS Research), NYC, NY
- 2003 Invited Speaker: “Treatment of HCV in Coinfected Patients”

Brown University Advanced Liver Disease Symposium, Newport, RI

- 2003 Invited Speaker: "Hepatitis C Treatment"  
AASLD Educational Symposium, Boston, MA
- 2004 Invited Speaker: "Treatment of HCV in Coinfected Patients"  
Symposium on Unanswered Questions in the Treatment of Hepatitis C, NYC, NY
- 2004 Invited Lecturer "HAART or Liver: HIV After the Cocktails"  
Grand Rounds, Beaumont Medical Center, Detroit, MI
- 2004 Invited Lecture: "Clinical Implications in Patients with HCV/HIV Coinfection"  
AASLD Annual Meeting, Boston, MA
- 2004 Invited Speaker: "Viral Kinetics: Steady State Ain't That Great"  
Multicenter Hemophilia Cohort Study Annual Meeting, Washington, DC
- 2004 Invited Speaker: "HCV/HIV Treatment"  
Colloquium on Issues in the Medical Management of HIV/HCV in IDUs, Collaborative Forum,  
Washington, DC
- 2004 Invited Speaker: "Clinical Implications in the use of Pegylated-interferons for HCV Treatment:  
Special Populations  
AGA Postgraduate course, DDW, New Orleans, LA
- 2004 Invited Speaker: "Viral Kinetics: Role in Prediction of Response"  
DDW Satellite Symposium, New Orleans, LA
- 2004 Invited Lecturer: "Liver Transplantation in the HIV-infected Patient: Is Now the Time?"  
Transplant Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI
- 2004 Invited Speaker: "Practical Strategies to Maximize Response to HCV Therapy"  
American College of Gastroenterology Annual Meeting, Orlando, FL
- 2004 Invited Speaker: "Disparities in HCV Treatment Response"  
Vanderbilt University Workshop on Disparities in the HIV Epidemic, Nashville, TN
- 2005 Invited Lecturer: "Hepatitis C and HIV"  
Grand Rounds, Virginia Commonwealth University, Richmond, VA
- 2005 Invited Speaker: "Hepatitis C Treatment and Prevention"  
Ohio Department of Health Symposium on HIV/STD Prevention, Columbus, OH
- 2005 Invited Speaker: "Hepatitis C and HIV"  
University of Kentucky Symposium on "HIV Management: An Evolving Science", Lexington,  
KY
- 2005 Invited Lecturer: "HCV/HIV Coinfection"  
Grand Rounds, Indiana University, Indianapolis, IN

- 2005 Invited Speaker: “HCV/HIV Coinfection”  
Symposium “Emerging Treatments for Liver and Complex GI Diseases”, San Francisco, CA
- 2006 Invited Speaker: “Treating HCV in the HIV-infected Patient”  
IAS-USA Symposium, “Improving the Management of HIV Disease”, New York City, NY
- 2006 Invited Lecturer: “Transplantatation of the HIV-Infected Patient”  
Transplant Grand Rounds, Northwestern University, Chicago, IL
- 2006 Invited Speaker: “Treating HCV”  
American Society of Addiction Medicine/NIDA Annual Conference, San Diego, CA
- 2006 Invited Speaker: “HCV/HIV Coinfection”  
Grand Rounds, Case Western Reserve-Metro Health, Cleveland, OH
- 2006 Invited Speaker: “Treating HCV/HIV Coinfection”  
Hepatitis Summit, Cleveland Clinic, Cleveland, OH
- 2007 Invited Lecturer: “HCV/HIV Coinfection”  
Infectious Disease Grand Rounds, Univ. of California-San Diego, San Diego, CA
- 2007 Invited Lecturer: “HCV/HIV Coinfection”  
Hepatology Grand Rounds, University of Pennsylvania, Philadelphia, PA
- 2007 Invited Lecturer: “Hepatitis C Treatment and Management”  
Grand Rounds, Univ. of Medicine and Dentistry of New Jersey, Newark, NJ
- 2008 Invited Speaker: “Hepatitis C Treatment in Hemophiliacs”  
National Hemophilia Foundation Annual Meeting, Denver, CO
- 2009 Invited Speaker: “HIV and Liver Disease”  
Annual Walter Reed Symposium, Washington, DC
- 2009 Invited Lecturer: “Hepatitis C/HIV Coinfection”  
Grand Rounds, University of Colorado Health Sciences Center, Denver, CO
- 2009 Invited Speaker: “Liver Disease for the Non-Hepatologist”  
IAS-USA HIV Symposium, Washington, DC
- 2009 Invited Speaker: “HCV/HIV Coinfection: Soup to Nuts”  
American Conference for the Treatment of HIV, Denver, CO
- 2009 Invited Speaker: “HCV in Hemophiliacs and Other Inherited Blood Disorders”  
Hemophilia of Georgia Annual Meeting, Raleigh, NC
- 2009 Invited Speaker: “Hepatitis E”  
HepDART, Kona, HI
- 2009 Invited Speaker/Moderator: “Hepatitis C Case Presentations”

47<sup>th</sup> Infectious Disease Society of America Annual Meeting, Philadelphia, PA

- 2010 Invited Speaker: “HCV Coinfections”  
American Conference for the Treatment of HIV, Denver, CO
- 2010 Invited Lecture: “Hepatitis E: One Virus, Many Faces”  
AASLD Postgraduate Course, Boston, MA
- 2010 Invited Lecture: “HCV/HIV Coinfection”  
Grand Rounds, National Institutes of Health, Bethesda, MD
- 2011 Invited Lecture: “Acute HCV in HIV-infected Patients”  
HepDART, Kauai, HI
- 2011 Invited Lecture: “Hepatitis B and C Coinfections in HIV-infected Patients”  
18<sup>th</sup> International Symposium on HCV and Related Viruses, Seattle, WA
- 2011 Invited Lecture, “HCV/HIV Coinfection”  
CONO, New York City, NY
- 2011 Invited Lecture: “Liver Failure Management”  
IAS-USA Workshop on HCV Management, Cleveland, OH and Washington, DC
- 2012 Invited Lecture: “Will DAA Combos, Without Ribavirin, Be an Option?”  
AASLD Single Topic Conference on HCV, Atlanta, GA
- 2012 Invited Lecture: “Management of HIV/HCV-Coinfected Patients With Advanced Liver Disease”  
Clinical Care Options Annual Course, San Francisco, CA
- 2012 Invited Lecture: “Managing Advanced Liver Disease in HIV”  
OPMAN, Miami, FL
- 2012 Invited Lecturer: “HCV/HIV Coinfection”  
Grand Rounds, University of Colorado Health Sciences Center, Aurora, CO
- 2012 Invited Lecturer: “HCV/HIV Coinfection”  
Infectious Disease Grand Rounds, Duke University, Durham, NC
- 2012 Invited Speaker: “HCV/HIV Coinfection”  
Univ. of California-Irvine GI/Liver Retreat, Palm Springs, CA
- 2012 Invited Lecturer: “Hepatitis E”  
Hepatology Grand Rounds, Univ. of Pennsylvania, Philadelphia, PA
- 2013 Invited Speaker: “HCV/HIV Coinfection”  
Virginia Commonwealth University Annual GI Review, Richmond, VA
- 2013 Invited Lecturer: “Hepatitis C/HIV Coinfection”

Northwestern University GI Research Conference, Chicago, IL

- 2013 Invited Speaker: “Hepatitis B Diagnosis and Prevention”  
OPMAN, Miami, FL
- 2013 Invited Speaker: “Management of the Treatment-naive HCV”  
Clinical Care Options Annual Hepatitis Course, New York City, NY
- 2013 Invited Speaker: “Hepatitis C and HIV”  
Robert Wood Johnson Annual GI Update Course, New Brunswick, NJ
- 2013 Invited Speaker: “Hepatitis E”  
AASLD Digestive Disease Week Symposium, Orlando, FL
- 2013 Invited Speaker: “Hepatitis C in HIV”  
Case Western Reserve Center for AIDS Research Conference, Cleveland, OH
- 2013 Invited Speaker: “Non-Invasive Markers of Hepatic Fibrosis vs. Liver Biopsy”  
ACTG Annual Retreat, Washington, DC
- 2013 Invited Speaker: “Hepatitis E- State of the Art”  
AASLD Annual Liver Meeting, Washington, DC
- 2014 Invited Speaker: “Liver Management”  
Conference on Retroviruses and Opportunistic Infections, Boston, MA
- 2014 Invited Lecturer: “Viral Kinetics in HCV”  
Maramorosch Lecture, Rutgers University, New Brunswick, NJ
- 2014 Invited Speaker: “Non-Invasive Testing- Is Biopsy Dead?”  
OPMAN, Miami, FL
- 2014 Invited Lecture: “Hepatitis E”  
Viral Hepatitis Grand Rounds, University of Pennsylvania, Philadelphia, PA
- 2014 Invited Speaker: “Should everyone with HCV/HIV Coinfection Be Treated Now?”  
AASLD/EASL Special Topic Conference on Hepatitis C, NYC, NY
- 2015 Invited Speaker: “Hepatitis C Coinfection”  
Univ. of California-Irvine Annual GI Update Course, Anaheim, CA
- 2015 Invited Speaker: “Hepatitis C and HIV”  
New Jersey Medical School Annual Update, Newark, NJ
- 2015 Invited Speaker: “HBV Cure”  
OPMAN, Orlando, FL
- 2015 Invited Speaker: “Hepatitis E”  
HepDART, Wailea, HI



- 2015 Invited Speaker: “Hepatology for the non-hepatologist”  
IAS-USA Regional HCV Course, Chicago, IL
- 2015 Invited Speaker: “Therapeutic Advances for HCV & HCV/HIV”  
Hepatology Update, Washington University, St. Louis, MO
- 2015 Invited Speaker: “Comorbidities and Hepatitis C”  
Institute for Human Virology Conference, Univ. of Maryland, Baltimore, MD
- 2016 Invited Lecturer: “HCV/HIV Coinfection”  
Grand Rounds, Indiana University, Indianapolis, IN
- 2016 Invited Speaker: “HIV Effects on Liver Fibrosis and Steatosis: A Themed Discussion”  
Conference on Retroviruses and Opportunistic Infections, Boston, MA
- 2016 Invited Speaker: “State of the Art-Prevention and Management of HBV Infection”  
Ryan White National Clinical Conference, Washington, DC
- 2016 Invited Speaker: “Viral Kinetics”  
Viral Hepatitis Research Conference, Centers for Disease Control, Atlanta, GA
- 2017 Invited Lecturer: “Hepatitis A, D, and E”  
Grand Rounds, UMDNJ-Rutgers, Newark, NJ
- 2017 Invited Speaker: “NAFLD/NASH in HIV”  
OPMAN, Orlando, FL
- 2017 Invited Lecturer: “Hepatitis B & HIV- Management, Screening and Testing”  
Infectious Diseases Division Lecture Series, Dartmouth Univ, Hanover, NH
- 2017 Invited Speaker: “Hepatitis E-What is It, How Do You Find It, Is It Harmful?”  
International Conference on Viral Hepatitis, Chicago, IL
- 2017 Invited Speaker: “Hepatology for the Non-Hepatologist”  
Arkansas Dept. of Health/IAS-USA Workshop, Little Rock, AR
- 2017 Invited Speaker: “HEV Update- Diagnostics and Management”  
HepDART, Kona, HI
- 2018 Invited Speaker: “Is NASH a Problem in HIV Patients?”  
OPMAN, Orlando, FL
- 2018 Invited Speaker: “HBV Prevention in HIV”  
7<sup>th</sup> HIV and Liver Disease Conference, Jackson, WY
- 2018 Invited Speaker: “Hepatology for the Non-Hepatologist”  
Maine Medical Center, IAS-USA Workshop, Portland, ME

- 2018 Invited Speaker: “Hepatitis A and E”  
AASLD/ALEH Symposium on Tropical Hepatology, San Francisco, CA
- 2018 Invited Speaker: “Issues in Liver Health and Disease”  
National Ryan White Conference, Washington, DC
- 2019 Invited Speaker: “HIV and Liver Disease”  
IAS-USA HIV Conference, Atlanta, GA
- 2019 Invited Speaker: “Fatty Liver Disease in HIV”  
OPMAN, Orlando, FL
- 2019 Invited Speaker: “Hepatic Encephalopathy”  
Grand Rounds, University of Indiana Medical School, Bloomington, IN
- 2019 Invited Speaker: “Hepatitis E as a Global Disease: From Epidemiology to Cure”  
HepDART, Lihue, Kauai
- 2020 Invited Speaker: “Prevention of Viral Hepatitis with Vaccines”  
OPMAN, (Virtual)
- 2020 Invited Speaker: Meet-the-Professor “Other Hepatidites”  
Infectious Disease Society of America Annual Meeting, (Virtual)
- 2021 Invited Speaker: “Prevention of Viral Hepatitis B”  
OPMAN (Virtual)
- 2021 Invited Speaker: “Management and Prevention of Hepatitis B”  
IAS-USA Webinar Series (Virtual)
- 2022 Invited Speaker: “Evaluation of abnormal liver tests in persons living with HIV”  
OPMAN, Orlando, FL

**International**

- 1994 Invited Speaker: “Thymosin alpha-1 treatment for hepatitis C”  
International Symposium on Thymic Peptides, Sardinia, Italy
- 1996 Invited Speaker: “Thymosin alpha-1 in viral hepatitis”  
International Symposium on Thymic Peptides, Frankfurt, Germany
- 1996 Invited Speaker: “Hepatitis C Treatment”  
Semina de Figueroa, Brazilian Society of Hepatology, Rio de Janeiro, Brazil
- 1997 Invited Speaker: “Treatment of hepatitis C”  
Friendship Hospital, Beijing, China

- 1997 Invited Speaker: “Treatment of hepatitis C”  
Sun Yat Sen University, Guangxiou, China
- 1997 Invited Speaker: “Treatment of hepatitis C”  
Viral Hepatitis Symposium, Cebu, Philippines
- 1998 Invited Speaker: “Treatment of hepatitis C”  
AGA/Spanish Gastroenterologic Society Post-graduate course, Oviedo, Spain
- 1999 Invited Speaker: “Treatment of Hepatitis C”  
Pan-Asian GI Association Annual Meeting, Chaing-Mai, Thailand
- 1999 Invited Speaker: “Hepatitis C Treatment Update”  
University GI Dinner Meeting, Taipei, Taiwan
- 2000 Invited Speaker: “Treatment of hepatitis C with immunomodulators”  
International Symposium on Immunomodulatory Agents, Eilat, Israel
- 2000 Invited Speaker: “The Drug Development Process”  
4<sup>th</sup> Shanghai International Symposium on Liver Cancer and Hepatitis, Shanghai, China
- 2002 Invited Lecture, “Clinical Implications in Patients with HIV/HCV Coinfection”  
Asian Pacific Society for the Study of Liver Disease (APASL) Annual Meeting, Taipei, Taiwan
- 2003 Invited Lecture: “Treatment of HCV in Coinfected Patients”  
8<sup>th</sup> International Meeting of GEMHEP, Paris, France
- 2004 Invited Lecture: “Treatment of HCV in Hemophiliacs”  
XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand
- 2005 Invited Lecture: “HCV Coinfection and Other Hepatic Complications of HIV Treatment”  
Second Joint Meeting of the AGA and the Japanese Society of Gastroenterology, Tokyo, Japan
- 2006 Invited Lecture: “HCV Treatment”  
41<sup>st</sup> EASL Annual meeting, Satellite Symposium on HCV, Vienna, Austria
- 2006 Invited Lecture: “HCV/HIV Coinfection”  
12<sup>th</sup> International Conference on Viral Hepatitis, Paris, France
- 2009 Invited Lecture: “TA-1 for the Treatment of HCV: Promise and Proof”  
International Symposium on Thymic Peptides and Immunomodulators, Sicily, Italy
- 2010 Invited Lecture: “HBV Treatment Issues Update”  
6<sup>th</sup> International Workshop on HIV and Coinfections, Tel Aviv, Israel
- 2010 Invited Lecture: “HCV Treatment in Hemophilia”  
World Hemophilia Congress, Buenos Aries, Argentina
- 2010 Invited Lecture: “Liver Failure: When HCV Treatments Have Failed”

Infectious Disease Society of America ID Week, Vancouver, Canada

- 2011 Invited Lecture: “HCV/HIV Coinfection”  
C-HEP, Barcelona, Spain
- 2011 Invited Lecture: “Hepatitis E and HIV”  
7<sup>th</sup> International Workshop on HIV and Coinfections, Milan, Italy
- 2012 Invited Speaker: “HBV and HIV Implications for Treatment and Management”  
8<sup>th</sup> International Workshop on HIV and Coinfections, Madrid, Spain
- 2016 Invited Speaker: “Hepatitis B- Future Therapies Towards a Cure”  
12<sup>th</sup> European Coinfection Workshop, Berlin, Germany
- 2017 Invited Speaker: “Hepatitis E in HIV”  
13<sup>th</sup> European Coinfection Workshop, Lisbon, Portugal
- 2017 Invited Speaker: “Hepatitis Diagnosis and Management”  
Ministry of Health, Kigali, Rwanda
- 2018 Invited Speaker: “Management of HCV/HIV Coinfection”  
Asian Pacific Association for the Study of Liver Annual Meeting, Delhi, India
- 2018 Invited Speaker: “Hepatitis E in Immunocompromised Patients”  
Global Hepatitis Summit, Toronto, Canada

## Report of Clinical Activities and Innovations

### Current Licensure and Certification

1986	Diplomate, National Board of Medical Examiners
1987-1994	Hawaii Medical License
1987-1995	New Jersey Medical License
1988-	Diplomate, American Board of Internal Medicine
1991-2011	Colorado Medical License
1991-2022	Diplomate, American Board of Internal Medicine in Gastroenterology
1994-	Ohio Medical License
2019-	Commonwealth of Massachusetts Medical License

### Practice Activities

1988-1989	Attending Physician	Internal Medicine Tripler Army Medical Center	2 months/year
1988-1999	Ambulatory Clinic	Internal Medicine Tripler Army Medical Center	8 ½ days/week
1991-1994	Attending Physician	Gastroenterology Consult Service Fitzsimons Army Medical Center	3 months/year
1991-1994	Ambulatory Clinic	GI/Hepatology Clinic/Endoscopy	2 ½ days/week
1994-	Attending Physician	Liver Consult Service	0.5-5 months/year

1994- Ambulatory Clinic Univ. of Cincinnati Medical Center  
Hepatology Clinic 1-4 ½ days/week

### **Report of Technological and Other Scientific Innovations**

Innovation Patent  
Composition and Method for treatment of Hepatitis C Patent # 07/878,372 and 08/145,660  
Filed 4May1992 and 4November1993, respectively  
Assigned to Department of the Army  
Licensed to SciClone Pharmaceuticals (expired)

Composition and Method for Treatment of Hepatitis B Patent # 07/914,673  
Filed 13July1992  
Assigned to Department of the Army (expired)

Method for Rapid Identification of IL28b Gene Polymorphisms U.S. Provisional Patent# 61/588,734  
Assigned to Univ. of Cincinnati (abandoned)

Method of Treating Hepatitis C Virus Infection With CCR5 Inhibitors U.S. Provisional Patent  
Application No. 62/143,938  
Assigned to Univ. of Cincinnati (abandoned)

### **Report of Education of Patients and Service to the Community**

1995-2006 Organizer, Hepatitis C Patient Support Group, Univ. of Cincinnati College of Medicine  
1998-2005 National Hemophilia Foundation Medical & Scientific Advisory Board (MASAC)  
member

### **Report of Scholarship**

#### **Publications, Peer Reviewed Publication in Print or Other Media**

1. **Sherman KE**. An inexpensive method for the anesthetization of insects. PLANT DIS REPORTER. 1977; 61:284-285.
2. **Sherman KE**, Maramorosch K. Present status of lethal yellowing disease of the coconut palm (Cocos nucifera). J PLANT CROPS. 1977; 5(2): 75-83.
3. **Sherman KE**, McIntosh AH. Baculovirus replication in a mosquito (Dipteran) cell line. INFECTION & IMMUNITY. 1979. 26(1):232-234. PMC414600
4. Yamada K, **Sherman KE**, Maramorosch K. In vivo infectivity of early and late passaged Heliothis zea polyhedra produced in tissue culture. APPL ENT ZOOL. 1981; 16:504-505.
5. Yamada K, **Sherman KE**, Maramorosch K. Serial passage of Heliothis zea singly embedded

nuclear polyhedrosis virus in a homologous cell line. *J INV PATH.* 1982; 39:185-191.

6. **Sherman KE**, Dodd RY (& the American Red Cross Alanine Aminotransferase Study Group). Alanine aminotransferase levels among volunteer blood donors: Geographic variation and risk factors. *J INFECTIOUS DIS.* 1982; 145(3):383-386.
7. Hornbrook MC, Dodd RY, Jacobs P, Friedman LI, **Sherman KE**. Reducing the incidence of non-A, non-B post-transfusion hepatitis by testing blood for alanine aminotransferase: Economic considerations. *NEW ENG J MED.* 1982; 307(21):1315-1321.
8. **Sherman KE**, Ku W, Sherman S, Stewart B, Povar G. Hepatitis B prevention: Practices and attitudes of physicians and dentists. *AM J PREV MED.* 1986; 2(5):290-296.
9. **Sherman KE**, Bornemann M. Amitriptylene and asymptomatic hypoglycemia. *ANN INTERN MED.* 1988; 109(8): 683-684.
10. **Sherman KE**, Jones C, Goldstein A, Naylor P. Low thymosin alpha-1 levels in patients chronically infected with the hepatitis B virus. *VIRAL IMMUNOL.* 1991; 4(3):195-199.
11. **Sherman KE**, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. *J INFECT DIS.* 1991; 163(2):414-415.
12. **Sherman KE**. Alanine aminotransferase in clinical practice. A review. *ARCH INTERN MED.* 1991; 151(2): 260-265.
13. **Sherman KE**, Jones C. Hepatotoxicity associated with piroxicam use. (Letter). *GASTROENTEROLOGY.* 1992; 103(1):354-355.
14. **Sherman KE**, Goodman Z. End stage liver disease in a 31 year-old man. *SEMIN LIVER DIS.* 1992; 12(3):340-34
15. **Sherman KE**, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J. Quantitative evaluation of hepatitis C virus RNA in patients with and without concurrent human immunodeficiency virus infections. *J CLIN MICROBIOL.* 1993; 31(10): 2679-2682.  
PMC265973
16. McGovern T, Holtzmuller K, **Sherman KE**, Smith M, Kadakia S, Inscoc B, Murphy T, See S, Morris W, Wong R, Sjogren M. Hepatitis C virus infection in U.S. families. *VIRAL HEPATITIS AND LIVER DISEASE.* 1994; 450-454.
17. Lawrence SP, **Sherman KE**, Lawson M, Goodman ZD. A 39 year man with chronic hepatitis. *SEM LIVER DIS* 1994;14(1):97-105.
18. Jahns F, Reddy V, **Sherman KE**. Ascites secondary to renal cell carcinoma: Diagnosis by laparoscopy. *J CLIN GASTROENTEROL* 1994; 18(3):259-60.
19. **Sherman KE**, Creager R, O'Brien J, Sargent S, Piacentini J, Thieme T. The use of oral fluid for hepatitis C antibody screening. *AM J GASTROENTEROL* 1994; 89(11):2025-2027.

20. **Sherman KE**, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. *J HEPATOL* 1994; 21(6):1040-1047.
21. Sudduth RH, DeAngelis S, **Sherman KE**, McNally PR. The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: A double blind randomized study. *GASTROINTEST ENDOSC* 1995;42(5):413-415.
22. **Sherman KE**, Lewey S, Goodman ZD. Talc in the liver of patients with chronic hepatitis C infection. *AM J GASTROENTEROL* 1995;90(12):2164-2166.
23. **Sherman KE**, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in HIV co-infected patients: Increased variability in the hypervariable envelope coding domain *HEPATOLOGY* 1996;23(4):688-694.
24. Root S, DeAngelis S, **Sherman KE**. Preliminary evaluation of an automated device for percutaneous liver biopsy. *J CLIN GASTROENTEROL* 1996;22(4):325-326.
25. Jain R, McLaren B, Bejarano P, **Sherman KE**. Diagnostic problem in clinical hepatology. A 69-year-old man with cholestatic liver disease. *SEMIN LIVER DIS* 1996;16(4):445-449.
26. **Sherman KE**, Mendenhall C, Thee DL, O'Brien J, Rouster, SD. Hepatitis C serotypes in nonalcoholic and alcoholic patients. *DIG DIS SCI*.1997; 42(11): 2285-2291.
27. Sickler JB, Simmon RA, Cobb DK, **Sherman KE**. Cutaneous necrosis associated with interferon alfa - 2b. *AM J GASTROENTEROL* 1998; 93(3):463-464.
28. **Sherman KE**, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG, Goodman ZD. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. *HEPATOLOGY*. 1998;27(4):1128-1135.
29. **Sherman KE**, Sherman SN. Interferon & Thymosin Alpha-1 Treatment of Chronic Hepatitis C Infection: A Meta-Analysis, in *THERAPIES FOR VIRAL HEPATITIS*. 1998;379-383
30. **Sherman KE**, Sickler J, Aranda-Michel J, Weber FL, Martin S, Whiting J, Hanto D. Rimantadine for treatment of hepatitis C infection in liver transplant recipients. *LIVER TRANSPL SURG* 1999;5(1):25-28.
31. Manocha AP, Sossenheimer M, Martin SP, **Sherman KE**, Venkatesan T, Whitcomb DC, Ulrich CD. Prevalence and predictors of severe acute pancreatitis in patients with acquired immune deficiency syndrome (AIDS). *AM J GASTROENTEROL*. 1999; 94(3):784-789.
32. Eyster ME, **Sherman KE**, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multi-transfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. *J INFECT DIS*. 1999;179(5):1062-1069.
33. **Sherman KE**, Rouster SD, Mendenhall C, Thee D. Hepatitis C RNA quasispecies complexity in patients with alcoholic liver disease. *HEPATOLOGY* 1999; 30(1):265-270.

34. Bessesen M, Ives D, Condreay L, Lawrence S, **Sherman KE**. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. *CLIN INFECT DIS* 1999; 28(5):1032-1035.
35. Mendenhall CI, Finkelman F, Means RT, **Sherman KE**, Nguyen VT, Grossman CE, Morris SC, Rouster S, Roselle GA. Cytokine response to BCG infection in alcohol-fed mice. *ALCOHOL* 1999; 19(1): 57-63.
36. Goedert JJ, Hatzakis A, **Sherman KE**, Eyster ME. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with HIV coinfection. *J INFECT DIS* 2001;184(9):1202-1205.
37. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, **Sherman KE**. Mechanism of indinavir-induced hyperbilirubinemia. *PROC NATL ACAD SCI USA* 2001; 98(22):12671-12676. PMC60112
38. **Sherman KE**, Rouster SD, Feinberg J. Prevalence and genotypic variability of TTV in HIV-infected patients. *DIG DIS SCI* 2001; 46(11): 2401-2407.
39. Bejarano PA, Koehler A, **Sherman KE**. Second opinion pathology in liver biopsy interpretation. *AM J GASTROENTEROL* 2001;96(11): 3158-3164.
40. **Sherman KE**, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *CLIN INFECT DIS* 2002;34(6):831-837.
41. **Sherman KE**. Diagnosis and management of the HCV/HIV coinfecting patient. *AIDS CLIN CARE* 2002; 14(5):39-43, 48.
42. Bleau BL, **Sherman KE**, Shaw MJ, Harford WV, Keate RF, Bracy WP, Fleischer DE, Balm R, Gostout CJ. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. *GASTROINTEST ENDOSC* 2002;56(1):1-6.
43. **Sherman KE**, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfecting with HCV and human immunodeficiency virus. *CLIN INFECT DIS* 2002;35(4):482-487.
44. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, deMoerloose P, White GC, Angiolillo AL, Luban NL, **Sherman KE**, Manco-Johnson M, Preiss L, Leissing C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A. End-stage liver disease in persons with hemophilia and transfusion-associated infections. *BLOOD* 2002;100(5):1584-1589
45. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, **Sherman KE**, ACTG 383 Study Team. Immune recovery is associated with persistent liver test flares, and is not impaired by hepatitis C virus in coinfecting subjects. *AIDS* 2002; 16(14):1915-1923.



46. Keiserman DR, Both CT, Mattos AA, Remiao J, Alexandre CO, **Sherman KE**. Intrafamilial transmission of hepatitis C virus in patients with hepatitis C and human immunodeficiency virus coinfection. *AM J GASTROENTEROL* 2003;98(4): 878-883.
47. Shiramizu B, Theodore D, Bassett R, Coel M, **Sherman KE**, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan TC, Reichman RC, Berggren R, Burning WJ, Brobst S, ACTG. Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the ACTG. *J ACQUIR IMMUNE DEFIC SYNDR* 2003; 33(3):329-335.
48. Blackard JT, Yang Y, Bordoni P, **Sherman KE**, Chung RT, ACTG 383 Study Team. Hepatitis C virus diversity in HIV-HCV coinfecting subjects initiating highly active antiretroviral therapy. *J INFECT DIS* 2004; 189(8):1472-1481.
49. Fleischer R, Boxwell D, **Sherman KE**. Nucleoside analogues and mitochondrial toxicity. *CLIN INFECT DIS* 2004; 38(8):79-80.
50. Zucker SD, **Sherman KE**. Beyond interferon for hepatitis C: living in the present while hoping for the future. *GASTROENTEROLOGY* 2004; 126:1487-1488.
51. Shire NJ, Rouster SD, Rajjicic N, **Sherman KE**. Occult hepatitis B in HIV infected patients. *J ACQUIR IMMUNE DEFIC SYNDR*. 2004; 36(3):869-875.
52. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven D, **Sherman KE**, Koziel MJ. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. *HEPATOLOGY* 2004; 40(1):125-132.
53. Keenan ED, Rouster SE, Shire NJ, Horn PS, **Sherman KE**. Complexity and diversity of hepatitis C virus RNA in African Americans and whites: Analysis of the envelope-coding domain. *J INFECT DIS*; 2004;190(3):511-514.
54. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, **Sherman KE**, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, ACTG A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV coinfecting persons. *N ENGL J MED* 2004; 351(5):451-459.
55. Morelli MS, Rouster SD, Giannella RA, **Sherman KE**. Clinical application of polymerase chain reaction to diagnose clostridium difficile in hospitalized patients with diarrhea. *CLIN GASTROENTEROL HEPATOL* 2004; 2(8):669-674.
56. Theodore D, Fried MW, Kleiner DE, Kroner BL, Goedert JJ, Eyster ME, Faust SP, **Sherman KE**, Kessler CM, Francis C, Aledort LM. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. *HAEMOPHILIA* 2004; 10(5):413-421.
57. Zucker SD, Horn PS, **Sherman KE**. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. *HEPATOLOGY* 2004;40(4):827-835.
58. Goedert JJ, Brown DL, Hoots K, **Sherman KE**. Human immunodeficiency and hepatitis virus

infections and their associated conditions and treatments among people with hemophilia. *HAEMOPHILIA* 2004; 10 (Suppl 4):205-210.

59. **Sherman KE**, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. *ARCHIVES OF INTERNAL MEDICINE* 2004; 164(21):2377-2382.
60. Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, **Sherman KE**. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. *BLOOD* 2005; 105(2):533-541.
61. **Sherman KE**, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, Horn PS. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. *GASTROENTEROL* 2005; 128(2):313-327.
62. Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, **Sherman KE**, ACTG A5088. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. *J INFECT DIS* 2005; 191(5):686-693.
63. Alatrakchi N, Graham CS, He Q, **Sherman KE**, Koziel MJ. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV mono-infection. *J INFECT DIS* 2005; 191(5):702-709.
64. Lienesch D, Morris R, Metzger A, Debuys P, **Sherman KE**. Absence of cyclic citrullinated peptide antibody in non-arthritis patients with chronic hepatitis C infection. *J RHEUMATOLOGY*. 2005 Mar;32(3):489-93
65. Graham CS, Wells A, Liu T, **Sherman KE**, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ, ACTG 5071 Study Team. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. *AIDS* 2005 May; 19(8):767-773
66. Shire NJ, **Sherman KE**. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: Past, present, and future. *CLIN INFECT DIS* 2005 July; 1 Suppl. 41: S63-S68
67. Shire NJ, **Sherman KE**. Management of HBV/HIV coinfecting patients. *SEMIN LIVER DIS* 2005; 25 Suppl. 1:48-57.
68. **Sherman KE**, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, DaSilva B. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naïve HCV-HIV coinfecting patients: Lopinavir-ritonavir versus nelfinavir. *CLIN INFECT DIS* 2005 October; 41(8):1186-1195.
69. Shire NJ, Welge JA, **Sherman KE**. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. *VACCINE* 2006 Jan 16; 24(3): 272-279.
70. Graham CS, Wells A, Liu T, **Sherman KE**, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ for the ACTG 5071 Study Team. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus coinfection. *AIDS* 2006 February; 20(3): 345-351.

71. Mrus JM, **Sherman KE**, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfectd with HIV/hepatitis C: are two viruses worse than one? *MED CARE* 2006 February; 44(2): 158-166. PMC1389699
72. Mandac JC, Chaudhry S, **Sherman KE**, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. *HEPATOLOGY* 2006 April; 43(4): 661-672.
73. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Fullmer B, Wu L, Rehm CA, Masur H, Lane HC, **Sherman KE**, Fauci AS, Kottlilil S. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: Class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfectd persons. *J INFECT DIS* 2006 April 15; 193(8): 1172-1177.
74. Mann EA, Stanford S, **Sherman KE**. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF- $\kappa$ B activation. *VIRUS RES* 121 (2006); 51-57.
75. Lienesch DW, **Sherman KE**, Metzger A, Shen GQ. Anti-Clq antibodies in patients with chronic hepatitis C infection. *CLIN EXP RHEUMATOL* (2006); 24(2): 183-185.
76. Schwarze-Zander C, Blackard JT, Zheng H, Addo MM, Lin W, Robbins GK, **Sherman KE**, Zdunek D, Hess G, Chung RT, ACTG A5071 Study Team. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV coinfectd patients receiving HCV treatment: importance of the GBV-C genotype. *J INFECT DIS*. (2006); 194(4): 410-419.
77. Zucker SD, Benedict M, **Sherman KE**. Letter to the Editor, Serum bilirubin and risk of colorectal cancer. *AILEMENT PHARM THER* 2006; 24: 1257-1259.
78. Peters MG, Anderson J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, **Sherman KE**, Swindells S, Polsky B; ACTG Protocol A5127 Team. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. *HEPATOLOGY* 2006; 44(5): 1110-1116.
79. Shire NJ, Horn PS, Rouster SD, Stanfors S, Eyster ME, **Sherman KE**, Multicenter Hemophilia Cohort HCV Study Group. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfectd patients with hemophilia. *HEPATOLOGY* 2006; 44(5): 1146-1157.
80. Blackard JT, Kang M, **Sherman KE**, Koziel MJ, Peters MG, Chung RT. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. *J INTERFERON CYTOKINE RES* 2006; 26(11): 834-838.
81. **Sherman KE**. New paradigms in the management of hepatitis C virus coinfections. *NAT CIN PRACT GASTROENTEROL HEPATOL*.2007; Jan 4(Suppl 1):S10-6.
82. Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, **Sherman KE**, The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. *JAIDS* 2007 Mar1;44(3):309-314

83. Alatrakchi N, Graham CS, Van der Vliet J, **Sherman KE**, Exley MA, Koziel MJ. Hepatitis C Virus (HCV) specific CD8+ cells produce TGF-beta that can suppress HCV-specific T cell responses. *J. VIROL.* 2007 Jun;81(11):5882-92. PMC1900307
84. Shire NJ, Welge JA, **Sherman KE**. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. *J VIRAL HEPAT* 2007; April 14(4): 239-248
85. Blackard JT, Kang M, Clair JB, Lin W, Kamegaya Y, **Sherman KE**, Koziel MJ, Peters MG, Anderson J, Chung RT, AIDS Clinical Trials Group A5071 Study Team. Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection. *J. INTERFERON CYTOKIN RES.* 2007; April 27(4):263-270.
86. **Sherman KE**, Goodman ZD, Sullivan ST, Faris-Young S, GILF Study Group. Liver biopsy in cirrhotic patients. *AM J GASTROENTEROL* 2007; April; 102(4):789-793.
87. Alatrakchi N, Graham CS, van der Vliet HJ, **Sherman KE**, Exley MA, Koziel MJ. Hepatitis C Virus (HCV) Specific CD8+ Cells Produce Transforming Growth Factor {beta} That Can Suppress HCV-Specific T-Cell Responses. *J VIROLOGY* 2007 June; 81 (11): 5882-92.
88. Shata MT, Barrett A, Shire NJ, Abdelwahab SF, Sobby M, Daef E, El-Kamary SS, Hashem M, Engle RE, Purcell RHm Strickland GT, **Sherman KE**. Characterization of hepatitis E-Specific Cell-Mediated Immune Response Using IFN-Gamma ELISPOT Assay. *J IMMUNOL METHODS.* 2007 Dec1;321 (1-2) :152-61. PMC2094100
89. Kemmer N, **Sherman KE**. What is the impact of HIV infection on survival after liver transplantation? *NATURE CLIN PRACT GASTROENTEROL HEPATOL.* 2008 Aug;5(8):426-7.
90. Diciara AJ, Atkinson M, Goodman Z, **Sherman KE**. Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. *MINERVA GASTROENTEROL.* 2008 Sep;54(3):307-15.
91. Atiq M, Shire NJ, Barrett A, Rouster SD, **Sherman KE**, Shata MT. Hepatitis E Virus Antibodies in Patients with Chronic Liver Disease. *EMERGING INFECTIOUS DISEASES.* 2009 Mar; Vol 15 (3); 479-81. PMC2681113
92. Shire NJ, Rao MB, Succop P, Buncher CR, Andersen JA, Butt AA, Chung RT, **Sherman KE**; AIDS Clinical Trials Group 5178 Study Group. Improving Noninvasive methods of Assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. *CLIN GASTROENTEROL HEPATOLOGY* 2009 April;7(4):471-80. nPMC3159915
93. Rashkin S, Rouster S, Goodman ZD, **Sherman KE**. T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients. *J VIRAL HEPATOLOGY* 2010 Mar;17(3):222-6. PMC3025412
94. Martin CM, Welge JA, Shire NJ, Shata MT, **Sherman KE**, Blackard JT. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. *CYTOKINE* 2009 Sep;47(3):194-8. PMC3031085

95. Blackard JT, Rouster SD, Nady S, Galal G, Marzuuk N, Rafaat MM, Daef E, El Din SS, Purcell RH, Emerson SU, **Sherman KE**, Shata MT. Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt. *J CLIN VIROLOGY* 2009 Oct;46(2):140-4. PMC2753377
96. Dryer PD, Limketkai BN, Martin CM, Ma G, **Sherman KE**, Taylor LE, Mayer KH, Jamieson DJ, Blackard JT. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naïve women. *J ANTIMICROB CHEMOTHER.* 2009 Nov;64(5):945-8. PMC2766823
97. **Sherman KE**, Rouster SD, Stanford S, Blackard JT, Shire N, Koziel M, Peters M, Chung RT; AIDS Clinical Trials Group 5071 Study Team. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. *J INFECT DIS.* 2010 Mar;201(5):712-9. PMC2827649
98. Barry CT, Avissar U, Asebrook M, Sostok MA, **Sherman KE**, Zucker SD. Use of a Standardized Patient Exercise to Assess Core Competencies During Fellowship Training. *J GRAD MED EDUC.* 2010 Mar;2(1):111-7. PMC2931209
99. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, **Sherman KE**, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfecting transplant recipients. *AM J TRANSPLANT.* 2010 May;10(5):1268-75. PMC 3155863
100. Martin CM, Welge JA, Shire NJ, Rouster SD, Shata MT, **Sherman KE**, Blackard JT. Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. *J VIRAL HEPAT* 2010 Aug;17(8):588-97. PMC3032083
101. **Sherman KE**, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; for the AIDS Clinical Trials Group A5178 Study Team. Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV Coinfected Patients (SLAM-C). *J ACQUIR IMMUNE DEFIC SYNDR.* 2010 Oct 1.
102. Blackard JT, Ma G, Limketkai BN, Welge JA, Dryer PD, Martin CM, Hiasa Y, Taylor LE, Mayer KH, Jamieson DJ, **Sherman KE**. Variability of the Polymerase gene (NS5B) in Hepatitis C Virus Infected Women. *J CLIN MICROBIOL.* 2010 Nov;48 (11):4256-9. PMC3020841
103. **Sherman KE**, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; AIDS Clinical Trials Group A5178 Study Team. Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV Coinfected Patients (SLAM-C). *J ACQUIR IMMUNE DEFIC SYNDR.* 2010 Dec 15;55(5):597-605. PMC3017670
104. Schmeltzer P, **Sherman KE**. Occult Hepatitis B: Clinical Implications and Treatment Decisions. *DIG DIS SCI.* 2010 Dec;55(12):3328-35. PMC3001399
105. Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, Jamieson DJ, Gardner L, **Sherman KE**. HIV Mono-Infection is Associated with FIB-4 – A noninvasive Index of Liver Fibrosis – In Women. *CLIN INFECT DIS.* 2011 Mar;52(5):674-80. PMC3106241

106. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, **Sherman KE**, Tashima KT. Incident Hepatitis C Virus Infection among US HIV–Infected Men Enrolled in Clinical Trials. *CLIN INFECT DIS*. 2011 Mar;52(6):812-8. PMC3106260
107. Eckman MH, Kaiser TE, Sherman KE. The Cost-Effectiveness of Screening for Chronic Hepatitis B Infection in the United States. *CLIN INFECT DIS* 2011 Jun;52(11):1294-306. PMC3097367
108. Butt AA, Umbleja T, Andersen JW, Chung RT, **Sherman KE**; ACTG A5178 Study Team. The incidence, Predictors and Management of Anemia and its Association with Virological Response in HCV/HIV Coinfected Persons Treated with Long-Term Pegylated Interferon Alfa 2A and Ribavirin. *ALIMENT PHARMACOL THER*. 2011 Jun;33(11):1234-44. PMC3184244
109. Chak E, Talal AH, **Sherman KE**, Schiff ER, Saab S. Hepatitis C Virus Infection in USA: An Estimate of True Prevalance. *LIVER INT*. 2011 Sep;31(8):1090-101.
110. **Sherman KE**, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. *N ENGL J MED*. 2011 Sep 15;365(11):1014-24.
111. Dayyeh BK, Gupta N, **Sherman KE**, de Bakker PI, Chung RT. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfecting persons undergoing peginterferon and ribavirin therapy. AIDS Clinical Trials Group A5178 Study Team. *PLoS ONE*. Oct 2011;6(10): PMC3189209
112. Blackard JT, Ma G, Martin CM, Rouster SD, Shata MT, **Sherman KE**. HIV Variability in the Liver and Evidence of Possible Compartmentalization. *AIDS RES HUM RETROVIRUSES* 2011 October;27(10): 1117-1126. PMC3186706
113. Kemmer NM, **Sherman KE**. Liver Transplantation Trends in the HIV Population. *DIG DIS SCI*. 2011 November;56(11):3393-3398. PMC3548236.
114. Soriano V, **Sherman KE**, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M. Challenges and Opportunities for Hepatitis C Drug Development in HIV-HCV Coinfected Patients. *AIDS*. 2011 Nov 28;25(18):2197-208
115. Blackard JT, Ma G, Welge JA, Martin CM, **Sherman KE**, Taylor LE, Mayer KH, Jamieson DJ. Analysis of a Non-Structural Gene Reveals Evidence of Possible Hepatitis C Virus (HCV) Compartmentalization. *J MED VIROL*. 2012 Feb;84(2):242-52. PMC3243959
116. Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE; ACTG A5178 Study Team. Extended Therapy with Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients. *HIV CLIN TRIALS*. 2012 Mar-Apr;13(2):70-82. PMC:3367320
117. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM,

**Sherman KE**, Zeuzem S, Kwong AD, Picchio G. Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. PLoS ONE. 2012;7(4):e34372. PMC:3325239

118. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, **Sherman KE**, Subramanian A, Millis JM, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odum J, Fox L, Stock PG; Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of Liver Transplant Recipients with Hepatitis C and Human Immunodeficiency Virus Coinfection. LIVER TRANSPL. 2012 Jun;18(6):716-26. PMC3358510
119. Butt AA, Umbleja T, Andersen JW, **Sherman KE**, Chung RT; for the ACTG A5178 Study Team. Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study. Clin Infect Dis. 2012 Sep;55(5):631-638. PMC3491848
120. Kong L, Cardona Maya W, Moreno-Fernandez ME, Ma G, Shata MT, **Sherman KE**, Chougnat C, Blackard JT. Low-Level HIV Infection of Hepatocytes. VIROLOGY JOURNAL 2012 Aug 9;9(1):157 PMC3607931
121. Martin CM, Welge JA, Rouster SD, Shata MT, **Sherman KE**, Blackard JT. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. J VIRAL HEPAT 2012 Oct;19(10):716-23. PMC3442934
122. Shata MT, Daef EA, Zaki ME, Abdelwahab SF, Marzuuk NM, Sobhy M, Rafaat M, Abdelbaki L, Nafeh MA, Hashem M, El-Kamary SS, Shardell MD, Mikhail NN, Strickland GT, **Sherman KE**. Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. TRANS R SOC TROP MED HYG 2012 Oct;106(10):613-8.
123. Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, **Sherman KE**. Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study. J VIRAL HEPAT 2012 Nov;19(11):792-800. PMC3468910
124. Ragni MV, Devera ME, Roland ME, Wong M, Stosor V, **Sherman KE**, Hardy D, Blumberg E, Fung J, Barin B, Stablein D, Stock PG. Liver Transplant Outcomes in HIV(+) Haemophilic Men. HAEMOPHILLIA 2013 Jan;19(1):134-40. Epub 2012 Jul 5
125. Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, **Sherman KE**, Butt AA. Therapy for HCV Infection Increases Survival of Patients with Pre-Treatment Anemia. CLIN GASTROENTEROL HEPATOL 2013; Jan; 31(13) 166-173.
126. Eckman MH, Talal AH, Gordon SC, Schiff E, **Sherman KE**. Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States. CLIN INFECT DIS 2013; May;56(10):1382-93. PMID 23392392.
127. Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, **Sherman KE**, Butt AA. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. CLIN GASTROENTEROL HEPATOL. 2013 Jun;11(6):741-747. PMID: 23376794.

128. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, **Sherman KE**, Zeuzem S, Picchio G, Kieffer TL. Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. *CLIN INFECT DIS*. 2013 Jul;57(2):221-9. PMID 23575197
129. Abdel-Hameed EA, Ji H, **Sherman KE**, Shata MT. Epigenetic Modification of FOXP3 in Patients with Chronic HIV Infection. *J ACQUIR IMMUNE DEFIC SYNDR* 2013 Jul 10. PMID 23846566
130. Sulkowski MS, **Sherman KE**, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial. *ANN INTERN MED* 2013 Jul 16; 159(2):86-96. PMID:23685940.
131. Erqou S, Mohanty A, McGinnis KA, Vanasse G, Freiberg MS, **Sherman KE**, Butt AA. Hepatitis C Virus Treatment and Survival in Patients with Hepatitis C and Human Immunodeficiency Virus Co-Infection and Baseline Anaemia. *J VIRAL HEPAT*. 2013 Jul;20(7):463-9. PMID: 23730839
132. Shata MT, Abdel-Hameed EA, Hetta HF, **Sherman KE**. Immune Activation in HIV/HCV-Infected Patients is Associated with Low-Level Expression of Liver Expressed Antimicrobial Peptide-2 (LEAP-2). *J CLIN PATHOL*. 2013 Aug 12. PMID: 23940131
133. Lin MV, Charlton AN, Rouster SD, Zamor PJ, **Sherman KE**. Hepatitis C NS3 Mutations in Haemophiliacs, HAEMOPHILIA. 2014 Apr 3.
134. **Sherman KE**, Terrault N, Barin B, Rouster SD, Shata MT. Hepatitis E Infection in HIV-Infected Liver and Kidney Transplant Candidates. *J VIRAL HEPAT*. 2014 Apr 28.
135. **Sherman KE**, Guedj J, Shata MT, Blackard JD, Rouster SD, Feinberg J, Sterling RJ, Goodman Z, Aronow BJ, Perelson AS. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. *SCIENCE TRANSLATIONAL MED*, 2014 July 23;6(246). PMID: 25101888.
136. Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V 3<sup>rd</sup>, Justice AC, **Sherman KE**; the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Virologic response and haematologic toxicity of boceprevir and telaprevir-containing regimens in actual clinical settings. *J VIRAL HEPAT*. 2014 Dec 18. PMID: 25524834
137. Butt AA, Yan P, Lo Re V 3<sup>rd</sup>, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, **Sherman KE**; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Liver fibrosis progression in hepatitis C virus infection after Seroconversion. *JAMA INTERNAL MED*. 2015 Feb 1;175(2):178-85 PMID: 25485735
138. Jensen D, **Sherman KE**, Hezode D, Pol S, Zeuzem S, Ledinghen V, Tran A, Elkhachab M, Younes ZH, Kugelmas M, Mauss S, Eveson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; on behalf of the



HALLMARK-QUAD Study Team. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. *J HEPATOL* 2015 Feb 19. PMID: 25703086

139. Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Nassar MI, Medhat A, **Sherman KE**, Shata MT. Colonic T cells are associated with HCV pathogenesis and Liver Pathology. *J GASTROENTEROL HEPATOL*. 2015 Feb 24. PMID: 25708446
140. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, **Sherman KE**, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N ENGL J MED*. 2015 Jul 21. [Epub ahead of print] PMID: 26196502
141. Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, **Sherman KE**. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. *Liver Int*. 2016 Apr;36(4):488-502. doi: 10.1111/liv.12993. Epub 2015 Nov 22. PMID: 26509462
142. Butt AA, Yan P, Shaikh OS, Chung RT, **Sherman KE**; ERCHIVES study. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. *Liver Int*. 2016 May;36(5):651-8. doi: 10.1111/liv.13036. Epub 2015 Dec 25. PMID:26616353
143. Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, **Sherman KE**, Shata MT. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. *Viral Immunol*. 2016 May;29(4):252-8. doi: 10.1089/vim.2015.0093. Epub 2016 Feb 17. PMID: 26885675
144. Lyons MS, Kunnathur VA, Rouster SD, Hart KW, Sperling MI, Fichtenbaum CJ, **Sherman KE**. Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. *Clin Infect Dis*. 2016 May 1;62(9):1066-71. doi: 10.1093/cid/ciw073. Epub 2016 Feb 21. PMID: 26908799
145. Judge CJ, Sandberg JK, Funderburg NT, **Sherman KE**, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD. CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. *J Acquir Immune Defic Syndr*. 2016 Jun 1. [Epub ahead of print] PMID: 27258231
146. **Sherman KE**, Ke R, Rouster SD, Abdel-Hameed EA, Park C, Palascak J, Perelson AS. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs. *Haemophilia*. 2016 Jul;22(4):543-8. doi: 10.1111/hae.12918. Epub 2016 Mar 3. PMID: 26936587
147. Blackard JT, Ma G, Polen C, DuBois JC, Gast J, Radens CM, Sterling RK, **Sherman KE**. Recombination among GB virus C (GBV-C) isolates in the United States. *J Gen Virol*. 2016 Jul;97(7):1537-44. doi: 10.1099/jgv.0.000477. Epub 2016 Apr 11. PMID: 27072634
148. Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Medhat A, Nassar MI, **Sherman KE**, Shata MT. Extra-hepatic infection of hepatitis C virus in the colon

tissue and its relationship with hepatitis C virus pathogenesis. *J Med Microbiol.* 2016 Aug;65(8):703-12. doi: 10.1099/jmm.0.000272. Epub 2016 May 10. PMID: 27166142

149. Blackard JT, Ma G, Polen C, DuBois JC, Gast J, Radens CM, Sterling RK, **Sherman KE**. Recombination among GB virus C (GBV-C) isolates in the United States. *J Gen Virol.* 2016 Jul;97(7):1537-44. doi: 10.1099/jgv.0.000477. Epub 2016 Apr 11. PMID: 27072634
150. Butt AA, Yan P, Shaikh OS, Chung RT, **Sherman KE**; ERCHIVES study. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. *Liver Int.* 2016 Sep;36(9):1275-83. doi: 10.1111/liv.13103. Epub 2016 Mar 24. PMID: 26928927
151. Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, **Sherman KE**, Shata MT. Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. *Arch Virol.* 2016 Nov;161(11):3161-9. doi: 10.1007/s00705-016-3015-4. Epub 2016 Aug 20. PMID: 27544760
152. Butt AA, Yan P, Marks K, Shaikh OS, **Sherman KE**; ERCHIVES Study Team. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. *Aliment Pharmacol Ther.* 2016 Oct;44(7):728-37. doi: 10.1111/apt.13748. Epub 2016 Jul 26. PMID: 27459341
153. Butt AA, Ren Y, Marks K, Shaikh OS, **Sherman KE**; ERCHIVES study Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. *Aliment Pharmacol Ther.* 2017 Jan;45(1):150-159. doi: 10.1111/apt.13837. Epub 2016 Nov 4. PMID: 27813162
154. **Sherman KE**, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. *World J Hepatol.* 2017 Feb 8;9(4):217-223. doi: 10.4254/wjh.v9.i4.217. PMID: 28217259 Free PMC Article
155. Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, **Sherman KE**. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. *J Acquir Immune Defic Syndr.* 2017 Mar 1;74(3):353-358. doi: 10.1097/QAI.0000000000001256. PMID: 27898525
156. Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ, Stosor V, Nissen N, Wong MT, **Sherman KE**, Stablein DM, Barin B. Hemophilia Liver Transplantation Observational Study. *Liver Transpl.* 2017 Jun;23(6):762-768. doi: 10.1002/lt.24688. PMID: 27935212
157. Judge CJ, Kostadinova L, **Sherman KE**, Butt AA, Falck-Ytter Y, Funderburg NT, Landay AL, Lederman MM, Sieg SF, Sandberg JK, Anthony DD. CD56bright NK IL-7R $\alpha$  expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. *J Leukoc Biol.* 2017 Jul;102(1):171-184. doi: 10.1189/jlb.5A1116-456R. Epub 2017 Apr 11. PMID: 28400540

158. Bari K, Lockett K, Kaiser T, Diwan T, Cuffy M, Schoech M, Safdar K, Blackard JT, Apewokin S, Paterno F, **Sherman KE**, Zucker SD, Anwar N, Shah SA. Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients. *Hepatology*. 2017 Dec 2. doi: 10.1002/hep.29704. [Epub ahead of print] PMID: 29205441
159. Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, **Sherman KE**, Butt AA; ACTG A5309s study team. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. *Drugs R D*. 2017 Dec;17(4):557-567. doi: 10.1007/s40268-017-0205-9. PMID: 28875397
160. Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, **Sherman KE**, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD. Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. *Vaccine*. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16. PMID: 29254840
161. Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, Lim JK, Morelli G, Kuo A, Levitsky J, **Sherman KE**, Frazier LM, Ramani A, Peter J, Akuskevich L, Fried MW, Nelson DR. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. *Sci Rep*. 2018 Feb 16;8(1):3199. doi: 10.1038/s41598-018-21303-2. PMID: 29453451
162. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, **Sherman KE**, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. *Clin Infect Dis*. 2018 Mar 16. doi: 10.1093/cid/ciy220. [Epub ahead of print] PMID: 29566246
163. Abdel-Hameed EA, Rouster SD, Boyce CL, Zhang X, Biesiada J, Medvedovic M, **Sherman KE**. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients. *Dig Dis Sci*. 2018 Mar;63(3):645-652. doi: 10.1007/s10620-017-4895-1. Epub 2018 Jan 12. PMID: 29330726
164. **Sherman KE**, Abdel-Hameed E, Rouster SD, Shata MTM, Blackard JT, Safaie P, Kroner B, Preiss L, Horn PS, Kottlilil S. Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic Blockade. *Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America*. 2018; PubMed [journal]PMID: 30239650
165. **Sherman KE**, Rouster SD, Kong LX, Shata TM, Archampong T, Kwara A, Aliota MT, Blackard JT. Zika Virus Exposure in an HIV-Infected Cohort in Ghana. *J Acquir Immune Defic Syndr*. 2018 Aug 15;78(5):e35-e38. doi: 10.1097/QAI.0000000000001718. PMID: 29771784 PMCID: PMC6037542 [Available on 2019-08-15]
166. Safaie P, Razeghi S, Rouster SD, Privitera I, **Sherman KE**. Hepatitis D diagnostics: Utilization and testing in the United States. *Virus research*. 2018; 250:114-117. PubMed [journal]PMID: 29596839

167. Eckman MH, Woodle ES, Thakar CV, Paterno F, **Sherman KE**. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. *Ann Intern Med*. 2018 Aug 21;169(4):214-223. doi: 10.7326/M17-3088. Epub 2018 Jul 10.
168. Eckman MH, Ward JW, **Sherman KE**. Cost Effectiveness of Universal Screening for HCV Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2018; PubMed [journal]PMID: 30201597
169. **Sherman KE**, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA. PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals. *Dig Dis Sci*. 2018 Sep 14. doi: 10.1007/s10620-018-5278-y. [Epub ahead of print]
170. Foster GR, dore GJ, Wang S, Grebely J, **Sherman KE**, Baumgarten A, Conway B, Jackson D, Asselah T, Sschwantler M, Tomasiewicz K, Aguilar H, Asatryan A, Hu Y, Mensa FJ. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. *Drug Alcohol Depend*. 2019 Jan 1; 194:487-494. PMID 30529905
171. Shata MTM, Abdel-Hameed EA, Rouster SD, Yu L, Liang M, Song E, Esser MT, Shire N, **Sherman KE**. HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles. *Pathog Immun*. 2019;4(1):39-65. doi: 10.20411/pai.v4i1.267. Epub 2019 Feb 13. PubMed PMID: 30815625; PubMed Central PMCID: PMC6388707.
172. **Sherman KE**, Rouster SD, Kong LX, Aliota MT, Blackard JT, Dean GE. Zika virus replication and cytopathic effects in liver cells. *PLoS One*. 2019 Mar 20;14(3):e0214016. doi: 10.1371/journal.pone.0214016. eCollection 2019.PMID: 30893357
173. Dao A, Cuffy M, Kaiser TE, Loethen A, Cafardi J, LUCKETT K, Rike AH, Cardi M, Alloway R, Govil A, Diwan T, **Sherman KE**, Shah S, Woodle ES. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. *Clin Transplant*. 2019 May 18:e13598. doi: 10.1111/ctr.13598. [Epub ahead of print]
174. Hu KG, Cui W, Rouster SD, **Sherman KE**. Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals. *WORLD J HEPATOL*. 2019 May 27;11(5):442-449 PMID 31183004.
175. **Sherman KE**, Abdel-Hameed EA, Ehman RL, rouster SD, Campa A, Martinez SS, Huang Y, Zarini GG, Hernandez J, Teeman C, Tamargo J, Kiu Q, Mandler r, Baum MK. Validation and refinement of noninvasive methods to assess hepatic fibrosis: Magnetic resonance elastography vs. Enhanced Liver Fibrosis Index. *DIG DIS SCI*. 2019 Aug. 29 PMID 31468264.
176. Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, Kottlilil S, Shata MT, **Sherman KE**. CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro. *PLoS One*. 2019 Oct 29;14(10):e0224523. doi: 10.1371. eCollection 2019.PMID: 31661521

177. Butt AA, Yan P, Aslam S, Abou-Samra AB, **Sherman KE**, Shaikh OS. Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES Clin Infect Dis. 2019 Dec 16. pii: ciz1097. doi: 10.1093/cid/ciz1097. [Epub ahead of print] PMID: 31840746
178. Eckman MH, Woodle ES, Thakar CV, Alloway RR, **Sherman KE**. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. Am J Kidney Dis. 2020 Jun;75(6):857-867. doi: 10.1053/j.ajkd.2019.11.005. Epub 2020 Feb 17. PMID: 32081494
179. Abdel-Hameed EA, Rouster SD, Kottlil S, **Sherman KE**. The enhanced liver fibrosis (ELF)-Index predicts hepatic fibrosis superior to FIB4 and APRI in HIV/HCV infected patients. Clin Infect Dis. 2020 May 27:ciaa646. doi: 10.1093/cid/ciaa646. Online ahead of print. PMID: 32459305
180. Bari K, Shah SA, Kaiser TE, Cohen RM, Anwar N, Kleesattel D, **Sherman KE**. Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial. Liver Transpl. 2020 Jun 30. doi: 10.1002/lt.25837. Online ahead of print. PMID: 32602616
181. Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, **Sherman KE**, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol. 2020 Aug 25:ASN.2020050686. doi: 10.1681/ASN.2020050686. Online ahead of print. PMID: 32843477
182. Gentene A, Bell AM, Pence A, Thomas K, Jakubecz C, Woolf SE, Guido MR, Mueller EW, **Sherman KE**. ANN PHARMACOTHER. 2021 May;55(5):565-574. PMID: 33016095
183. Tamargo JA, Campa A, Martinex SS, **Sherman KE**, Zarini G, Meade CS, Mandler RN, Baum MK. Cognitive impairment among people who use heroin and fentanyl: Findings from the Miami Adult Studies on HIV (MASH) Cohort. J PSYCHOACTIVE DRUGS. 2021 Jul-Aug;53(3): 214-223. PMID 35225878
184. Baum MK, Tamargo JA, Ehman RL, **Sherman KE**, Chen J, Liu Q, Mandler RNA, Teeman C, Martinez SS, Campa A. Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort. DRUG ALCOHOL DEPEND. 2021 Mar 1:220 PMID 33508691.
185. Tamargo, **Sherman KE**, Campa A, Martinez SS, Li T, Hernandez J, Teeman C, Mandler RN, Chen J, Ehman RL, Baum MK. Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. AM J CLIN NUTR. 2021 Mar 11;113(3):593-601. PMID 33515016.

186. Tamargo JA, Meade CSS, Campa A, Martinex SS, Li T, **Sherman KE**, Baum MK. Food insecurity and cognitive impairment in the Miami Adult Studies on HIV (MASH) Cohort. *J NUTR*. 2021 Apr 8;151(4):979-986. PMID 33561209
187. **Sherman KE**, Kottlilil S, Rouster SD, Abdel-Hameed EA, Boyce CL, Meeds HL, Terrault N, Shata MT. Hepatitis E infection in a longitudinal cohort of hepatitis C virus and HCV/HIV coinfecting persons. *AIDS RES HUM RETROVIRUSES*. 2021 Jul;37(7):534-541. PMID 33794657
188. **Sherman KE**, Rouster SD, Meeds, H, Tamargo J, Chen J, Ehman R, Baum M. PNPLA3 Single nucleotide polymorphism prevalence and association with liver disease in a diverse cohort of persons living with HIV. *BIOLOGY*. 2021 MAR 21;10(3):242 PMID 33800964
189. Kong L, Karns R, Shata MTM, Brown JL, Lyons MS, **Sherman KE**, Blackard JT. The synthetic opioid fentanyl enhances viral replication in vitro. *PLoS One*. 2021 Apr 14;15(4) PMID 33852610
190. Jose A, Shah SA, Anwar N, Jones CR, **Sherman KE**, Elwing JM. Pulmonary vascular resistance predicts mortality and graft failure in transplantation patients with portopulmonary hypertension. *LIVER TRANSPL*. 2021 May 8 PMID 33964116
191. Tamargo JA, Hernandex-Boyer J, Teeman C, Martin HR, Huang Y, Johnson A, Campa A, Martinez SS, Li T, Rouster SD, Meeds HL, **Sherman KE**, Baum MK. Immune activation : A link between food insecurity and chronic disease in people living with HIV. *J INFECT DIS*. 2021 May 16 PMID 33993311
192. **Sherman KE**, Meeds HL, Rouster SD, Abdel-Hameed EA, Hernandez J, Tamargo J, Chen J, Ehman RL, Baum M. Soluble CD163 identifies those at risk for increased hepatic inflammation & fibrosis. *OFID*. 2021 Apr 22;8(6) PMID 34104667
193. Gentene AJ, Bell AM, Pence A, Thomas K, Jakubecz C, Stacy E, Woolf B, Guido MR, Mueller EW, **Sherman KE**. *Ann Pharmacother*. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals. 2021 May;55(5):565-574. doi: 10.1177/1060028020964117. Epub 2020 Oct 5. PMID: 33016095
194. Eckman MH, Adejare AA, Duncan H, Woodle ES, Thakar CV, Alloway RR, **Sherman KE**. Incorporating Patients' Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. *MDM Policy Pract*. 2021 Oct 29;6(2):23814683211056537. doi: 10.1177/23814683211056537. eCollection 2021 Jul-Dec. PMID: 34734119
195. Abdel-Hameed EA, Rouster SD, Kottlilil S, **Sherman KE**. The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients. *Clin Infect Dis*. 2021 Aug 2;73(3):450-459. doi: 10.1093/cid/ciaa646. PMID: 32459305.
196. Blackard JT, Sherman KE. Drugs of Abuse and Their Impact on Viral Pathogenesis. *Viruses*. 2021 Nov 29;13(12):2387. doi: 10.3390/v13122387. PMID: 34960656

### **Proceedings of meetings and other non-peer reviewed research publications**

1. **Sherman KE**, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. HEPATOLOGY 2007, June; 45 (6) :1566-77
2. **Sherman KE**, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: Conference proceedings. HEPATOLOGY 2010, March; 51(3):1046-54
3. **Sherman KE**, Thomas DL, Chung RT. Human Immunodeficiency Virus and Liver Disease Forum 2010: Conference proceedings. HEPATOLOGY. 2011 Dec;54(6):2245-53.
4. **Sherman KE**, Thomas D, Chung RT. Human Immunodeficiency Virus and Liver Disease Forum 2012. HEPATOLOGY 2013 Jul 31. PMID 23904401
5. **Sherman KE**, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology. 2015 Dec;62(6):1871-82. doi: 10.1002/hep.28150. Epub 2015 Oct 20. PMID: 26340591
6. **Sherman KE**, Peters MG, Thomas D. HIV and Liver Disease: A Comprehensive Update. Hepatology Communications. 2017 November 06; 1(10):987.
7. **Sherman KE**, Peters, MG, Thomas D. HIV and the Liver. Topics in Antiviral Therapy. 2019 July/August 27(3).

### **Reviews, chapters, monographs and editorials**

1. **Sherman KE**. Multiple virus interactions. *in* VIRAL INSECTICIDES FOR BIOLOGICAL CONTROL (Maramorosch & Sherman, Eds.) Academic Press, N.Y. 1985; pp. 735-753.
2. **Sherman KE**. Considerations in the large-scale and commercial production of viral insecticides. *in* VIRAL INSECTICIDES FOR BIOLOGICAL CONTROL (Maramorosch & Sherman, Eds.) Academic Press, N.Y. 1985; pp. 757-774.
3. **Sherman KE**. Protecting crops with viruses. HIGH TECHNOLOGY. 1985. October; 56-58.
4. **Sherman KE**. Alanine aminotransferase in clinical practice: A review. ARCH INTERNAL MED. 1991; 151:260-265.
5. **Sherman KE**. Alanine aminotransferase: A nonspecific marker of liver disease. (Letter) ARCH INTERN MED. 1992; 152:213.
6. **Sherman KE**. Evaluation of abnormal liver tests *in* GASTROENTEROL SEC (P McNally, Ed.) 1996;pp. 92-96.
7. **Sherman KE**. Viral hepatitis *in* GASTROENTEROL SEC (P McNally, Ed.) 1996;pp. 97-103.

8. Aranda-Michel J, **Sherman KE**. Tests of the Liver: Use and Misuse. *GASTROENTEROLOGIST* 1998;6:34-43
9. Meyer CA, White CS, **Sherman KE**. Diseases of the hepatopulmonary axis *in* *RADIOGRAPHICS*. 2000 May-June; 20(3): pp 687-698.
10. Sickler J, **Sherman KE**. Hepatitis C Virus Infection: The Evaluation & Treatment of the Female Patient *in* *FEMALE PATIENT* 2000; 25 (June).
11. **Sherman KE**. Evaluation of Abnormal Liver Tests *in* *GI LIVER SECRETS: SECOND EDITION* (P McNally, Ed) 2001; pp. 93-98
12. **Sherman KE**. Viral Hepatitis *in* *GI / LIVER SECRETS: SECOND EDITION* (P McNally, Ed.) 2001; pp.99-106
13. **Sherman KE**. Liver Disease and Antiretroviral Therapy *in* *HIV / AIDS ANNUAL UPDATE* 2001; pp. 103-114
14. Isler BM, **Sherman KE**. Treatment of Chronic Hepatitis B and hepatitis C: Human Immunodeficiency Virus Coinfected Patients *in* *MNGT OF CHRONIC VIRAL HEP* 2001; 11; pp. 295-318
15. Keiserman DR, **Sherman KE**. Hepatitis C & HIV Coinfection. *in* *UPDATE IN HEPAT: HCV VIRAL INFECT* 2002; pp. 63-76
16. **Sherman KE**. Implications of Peginterferon use in Special Populations Infected with HCV. *SEMIN LIVER DIS* 2003; 23:47-52
17. **Sherman KE**. HCV & HIV: A Tale of Two Viruses *in* *GASTROENT DISORD* 2004; 4:Suppl 1; pp 48-54.
18. Sherman KE. The HIV-HCV Relationship: Viral Kinetics and Treatment Approaches in Coinfection. *INFECTIOUS DISEAS SPECIAL EDITION* 2004; Suppl 1; pp 58-67.
19. Chun S, **Sherman KE**. Treatment of hepatitis C virus/HIV coinfection. *CLIN LIVER DIS* 2005 Aug; 9(3): 525-533, ix.
20. Shire NJ, **Sherman KE**. Management of HBV/HIV-coinfected patients. *SEMIN LIVER DIS* 2005; 25 Suppl. 1: 48-57.
21. **Sherman KE**. Treatment of hepatitis C virus and human immunodeficiency virus co-infection. *CLIN GASTROENTEROL HEPATOL* 2005 October; 3 (10 Suppl 2): S118-121.
22. Shire NJ, Sherman KE. Vaccination Against Hepatitis A and B in Patients with HIV. *CURRENT HEPATITIS REPORTS* 2006 May, 5(Num 2): 63-67
23. Shire NJ, **Sherman KE**. Management of hepatitis B virus in HIV-positive patients. *MINERVA GASTROENTEROL DIETOL* 2006 March; 52(1): 67-87.



24. Neff GW, Jayaweera D, **Sherman KE**. Drug-Induced Liver Injury in HIV Patients. *GASTROENTEROLOGY & HEPATOL* 2006 June; 2 (Issue 6): 430-437.
25. Blackard JT, Kemmer N, **Sherman KE**. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. *HEPATOLOGY* (2006); 44(1): 15-22.
26. Shire NJ, Blackard JT, Shata MA, **Sherman KE**. Occult Hepatitis B Virus: Epidemiologic, Virologic, and Immunologic Characteristics. *PROGRESS IN HEPATITIS B RESEARCH* 2007; 1-35.
27. Zamor PJ, **Sherman KE**. Normal ALT Levels and Advanced Fibrosis in HCV/HIV – Coinfected Patients. *AIDS CLINICAL CARE* 2007 October; Vol 19, No. 10: pg 88.
28. Blackard JT, **Sherman KE**. Hepatitis C virus coinfection and superinfection. *J INFECT DIS* 2007; February 15; 195(4): 519-524.
29. Blackard JT, Shata MT, Shire NJ, **Sherman KE**. Acute hepatitis C virus infection: a chronic problem. *HEPATOLOGY*. 2008 Jan;47(1):321-31. PMC2277496
30. Blackard JT, **Sherman KE**. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? *J VIRAL HEPATITIS*. 2008 May;15(5):323-30. PMC3526832
31. Martin N, Chung R, **Sherman KE**. Hepatic and Hepatobiliary Diseases. *AIDS THERAPY, THIRD EDITION* 2008 (Churchill Livingstone); pp. 1355-1381.
32. Gordon SC, **Sherman KE**. Treatment of HBV/HCV coinfection: releasing the enemy within. *GASTROENTEROLOGY* 2009 Feb;136(2):393-6. (editorial)
33. **Sherman KE**. Thymosin Alpha 1 for Treatment of Hepatitis C Virus: Promise and Proof. *ANN NY ACADEMY SCIENCE* 2010 Apr; 1194:136-40
34. Ragni MV, **Sherman KE**, Jordan JA. Viral Pathogens. *HAEMOPHILIA* 2010 July; Vol 16, (Suppl 5):40-46.
35. Kemmer NM, **Sherman KE**. Hepatitis C-related arthropathy: Diagnostic and treatment considerations. *J MUSCULOSKELET MED*. 2010 Sept;27(9):351-354. PMC3103264
36. **Sherman KE**. Advanced Liver Disease: What Every Hepatitis C Virus Treater Should Know. *TOPICS IN ANTIVIRAL MEDICINE™* 2011 August/September; Vol 19, Issue 3:121-125.
37. Hernandez MD, **Sherman KE**. HIV/Hepatitis C Coinfection Natural History and Disease Progression. *CURR OPIN HIV AIDS*. 2011 Nov;6(6):478-82. PMC3293393
38. **Sherman KE**. Hepatitis E Virus Infection: More Common than Previously Realized? *GASTROENTEROL HEPATOL (NY)*. 2011 Nov;7(11):759-61. PMC3264930
39. Thomas DL, Bartlett JG, Peters MG, **Sherman KE**, Sulkowski MS, Pham PA. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. *CLIN INFECT DIS* 2012 Apr;54(7):979-83. PMC3404695

40. Jennings CL, **Sherman KE**. Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. *CURR HIV/AIDS REP*. 2012 Sep;9(3):231-7. PMC3551247
41. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, **Sherman KE**, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. *HEPAT RES TREAT* 2012;138302. PMC3472509
42. **Sherman KE**. Therapeutic Approach to the Treatment-Naive Patient With Hepatitis C Virus Genotype 1 Infection: A Step-by-Step Approach. *CLIN INFECT DIS*. 2012 Nov;55(9):1236-41.
43. **Sherman KE**. Managing adverse effects and complications in completing treatment for hepatitis C virus infection. *TOP ANTIVIR MED* 2012 Oct-Nov;20(4):125-8.
44. Soriano V, Barreiro P, **Sherman KE**. The Changing Epidemiology of Liver Disease in HIV Patients. *AIDS REV* 2013; Jan-Mar;15(1):25-31
45. Schmidt WN, Nelson DR, Pawlotsky JM, **Sherman KE**, Thomas DL, Chung RT. Direct Acting Antiviral Agents and the Path to Interferon Independence. *CLIN GASTROENTEROL HEPATOL*. 2013 Jul 17. PMID 23872239.
46. Sherman AC, **Sherman KE**. Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM. *Curr HIV/AIDS Rep*. 2015 Jul 25. [Epub ahead of print] PMID: 26208812
47. Shire NJ, **Sherman KE**. Epidemiology of Hepatitis C Virus: A Battle on New Frontiers. *GASTROENTEROL CLIN NORTH AM*. 2015 Dec;44(4):699-716. PMID: 26600215
48. **Sherman KE**, Shah VH. Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia. *Gastroenterology*. 2018 Feb;154(3):453-456. doi: 10.1053/j.gastro.2017.10.047. Epub 2017 Nov 14. No abstract available. PMID: 29154778
49. Murrison LB, **Sherman KE**. The Enigma of Hepatitis E Virus. *Gastroenterol Hepatol (N Y)*. 2017 Aug;13(8):484-491. PMID: 28867980
50. Soriano V, **Sherman KE**, Barreiro P. Hepatitis delta and HIV infection. *AIDS*. 2017 Apr 24;31(7):875-884. doi: 10.1097/QAD.0000000000001424. PMID: 28121714
51. **Sherman KE** and Sterling RK. HIV and Liver Disease in Zakim and Boyer's *HEPATOLOGY: A Textbook of Liver Disease*, 2018 (Eds., AJ Sanyal, TD Boyer, KD Lindor, NA Terrault).
52. **Sherman KE** and Kottlilil S, Hepatitis A and E in Schiff's *DISEASES OF THE LIVER* (Eds. ER Schiff, WC Maddrey, KR Reddy), 12<sup>th</sup> Edition, 2018 Wiley Blackwell
53. Blackard JT, **Sherman KE**. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). *Reviews in Medical Virology*. 2018; 28(4):e1984. NIHMSID: NIHMS994402 PubMed [journal]PMID: 29761585 PMCID: PMC6233878

54. Abutaleb A, **Sherman KE**. A changing paradigm: Management and treatment of the HCV/HIV coinfecting patient. *Hepatology International*. 2018 Nov; 12(6):500-509 PMID: 30248230
55. Narayanan S, Abutaleb A, **Sherman KE**, Kottilil S. Clinical features and determinants of chronicity in hepatitis E infection. *J Viral Hepatitis*. 2019 Jan 12 (Epub ahead of print). PMID: 30636092.
56. Seth A, **Sherman KE**. Fatty liver disease in persons living with HIV. *Top Antivir Med*. 2019 May;27(2):75-82. PMID: 31136997
57. Farooq PD, **Sherman KE**. Hepatitis B vaccination and waning immunity in persons living with HIV. *Curr HIV/AIDS Rep*. 2019 Aug 29. PMID 31468298.
58. Seth A, **Sherman KE**. Hepatitis E: What We Think We Know. *Clin Liver Dis (Hoboken)*. 2020 Mar 2;15(Suppl 1):S37-S44. doi: 10.1002/cld.858. eCollection 2020 Feb. PMID: 32140212
59. Seth A, **Sherman KE**. Editorial: HCV Cure is the Start of the End For Those With Advanced Fibrosis/Cirrhosis. *Clin Infect Dis*. 2020 May 9:ciaa509. doi: 10.1093/cid/ciaa509. Online ahead of print. PMID: 32386202

#### Clinical Guidelines and Reports

1. **Sherman KE**, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D; FDA Antiviral Products Advisory Committee. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. *HEPATOLOGY*. 2007 Dec;46(6):2014-20.
2. Kaplan JE<sup>1</sup>, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep*. 2009 Apr 10;58(RR-4):1-207.  
*Hepatitis B Virus Infection*, Leader, **Kenneth Sherman, MD, PhD**, University of Cincinnati, Cincinnati, OH, Members, Barbara McGovern, MD, Tufts University School of Medicine, Jamaica Plain, MA, Mindie Nguyen, MD, MAS, Stanford University, Palo Alto, CA, Marion Peters, MD, University of California, San Francisco, San Francisco, CA
3. Chung RT, Davis GL, Jensen DM, Masur H, Saag MS, Thomas DL, Aronsohn AI, Charlton MR, Feld JJ, Fontana RJ, Ghany MG, Godofsky EW, Graham CS, Kim AY, Kiser JJ, Kottilil S, Marks KM, Martin P, Mitruka K, Morgan TR, Naggie S, Raymond D, Reau NS, Schooley RT, **Sherman KE**, Sulkowski MS, Vargas HE, Ward JW, Wyles DL. AASLD IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *HEPATOLOGY*. 2015 Sep;62(3):932-54 Epub 2015 Aug 4.

4. **Sherman KE**, Thio CL. Treatment of chronic hepatitis B in the HIV-infected patient. UpToDate. Last updated September 21, 2020
5. **Sherman KE**, Thio CL. Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient. UpToDate. Last updated September 18, 2019
6. **Sherman KE**, Thio CL. Prevention of hepatitis B virus infection in the HIV-infected adult. UpToDate. Last updated July 31, 2019
7. **Sherman KE**, Thio CL. Pretreatment evaluation of chronic hepatitis B virus infection in the HIV-infected patient. UpToDate. Last updated September 6, 2019
8. **Sherman KE**. Hepatitis E Virus Infection. UpToDate. Last updated October 22, 2019

### **Books/Textbooks for the Medical or Scientific Community**

1. Maramorosch K, **Sherman KE**. (Eds.) Viral Insecticides for Biological Control. Academic Press, N.Y. 1985
2. **Sherman KE** (Ed). HIV and Liver Disease. Springer. 2012

### **Thesis**

1. **Sherman KE**. Replication of a Lepidopteran Baculovirus in cultured mosquito cells. Ph.D. Thesis. University Microfilm International, Ann Arbor. 1980

### **Nonprint Materials**

GenBank Submission (n=1668)

Results by taxon  
 Hepacivirus C (1496)  
 Human immunodeficiency virus 1 (105)  
 Hepatitis B virus (58)  
 Hepatitis E virus (5)  
 GB virus C (4)

### **Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings**

#### **Abstracts**

1. **Sherman KE**, Maramorosch K. Feeding the leafhopper, *Macrostelus fascifrons* on an artificial diet containing the aster yellows spiroplasma. PROC AMER PHYTOPATH SOC. 1977;4:197.
2. **Sherman KE**, McIntosh AH, Maramorosch K. *In vitro* interaction of mosquito cells with a Lepidopteran baculovirus. ABSTR AMER SOC MICROBIOL 1980;273.

2. **Sherman KE**, Dodd RY. The association of elevated ALT levels with genetically determined characteristics in a donor population. *TRANSFUSION*. 1981;21:606-607.
3. Jacobs P, Dodd RY, Hornbrood MC, Friedman LI, **Sherman KE**. Reducing the incidence of non-A, non-B posttransfusion hepatitis by ALT testing. *TRANFUSION* 1981;21:613.
4. **Sherman KE**, Becker GA, McGowan EI, Rivers SL, Sabin GM, Westphal RC, Dodd RY. A study of ALT levels in a geographically distributed volunteer donor population. in *Viral Hepatitis* (Szmuness, Alter & Maynard, eds.) Franklin Inst. Press, Philadelphia. pp. 827-828.
5. **Sherman KE**, Nath N, Dodd RY. Serologic markers of hepatitis A, B and herpes virus infection among blood donors; Relationship to serum transaminase levels. *ABSTR AMER SOC MICROBIOL*. 1982;C63.
6. Nath N, **Sherman KE**, Pielach M, Hoffman-Panetta K, O'Neill M, Mundon FK, Dodd RY. Antibody to CMV, EB, and hepatitis A viruses among healthy adults in the United States in *CMV Pathogenesis and Prevention of Human Infection* (Plotkin, Ed.), Alan Liss Inc. N.Y. 1984; pp.454.
7. **Sherman KE**, Jones C, Goldstein A. Thymosin alpha-1 levels in chronic hepatitis B infection. *ABSTR AMER SOC MICROBIOL*. 1987;pp 313.
8. **Sherman KE**, Jones C. Piroxicam hepatotoxicity in a hepatitis B carrier. *Army ACP*. San Francisco. 1988.
9. **Sherman KE**, Fedalei A, Seal L, Hamill R. Evaluation of circulating T-cell memory response to HBsAg in antibody negative hepatitis B vaccine recipients. *GASTROENTEROLOGY*. 1990. 98(Supp):A474.
10. **Sherman KE**, O'Brien J, Gutierrez AG. Evaluation of sample preparation methodologies for detection of hepatitis B genomic DNA by PCR. *HEPATOLOGY* 1991.14:219A.
11. **Sherman KE**, O'Brien J, Gutierrez AG, Morse P, Freeman S, Andron L, Harrison S. Serologic and genomic markers of viral hepatitis in patients with HIV infection. *GASTROENTEROLGOY*. 1992;102(4):A887.
12. McGovern TW, Holtzmuller KC, Smith MA, **Sherman KE**, Kepczyk T, Morris E, Heming P, Wong R, Murphy J, Sjogren MH. Hepatitis C transmission in sexual but not in casual contact of index cases. *HEPATOLOGY*. 1992;17
13. **Sherman KE**, O'Brien J, Urdea M, Chan C, Wilber J, Gutierrez A, Harrison S. Quantitative HCV determination by two methods in patients with and without concurrent HIV infection. *HEPATOLOGY*. 1992;17.
14. **Sherman KE**, Pinto PC. Cyclosporine treatment of Type 1 autoimmune chronic active hepatitis. *HEPATOLOGY*. 1992;17.
15. Sjogren M, McGovern T, Holtzmuller K, **Sherman KE**, Kadaki S, Morris E, Inscoc K, Wong R. Household transmission of hepatitis C (HCV): Sequence analysis of viral isolates. *VIRAL*

HEPATITIS (VIII International Congress).

16. **Sherman KE**, Lieberman MM, Fagarason M, Goldstein AL. Thymosin alpha-1 and circulating T-cell subsets in patients with chronic hepatitis C infection. *HEPATOLOGY*. 1993;18:85A
17. Davis DR, McDermott MT, **Sherman KE**. Significance of thyroid test abnormalities in patients infected with the hepatitis C virus. *HEPATOLOGY*. 1993;18:229A.
18. **Sherman KE**, Creager RL, O'Brien J, Thieme T. Oral fluid testing as a modality for HCV testing. *GASTROENTEROLOGY*. 1994;106:A982.
19. Sudduth RH, DeAngelis S, **Sherman KE**, McNally PR. The effectiveness of simethicone in improving visability during colonoscopy when given with a sodium phosphate solution: A double blind randomized study. *AM J GASTRO* 1994; 89:1699. 9, Page 1699.
20. **Sherman KE**, Sjogren MH, Creager RL, Freeman S, O'Brien J, Root S, Davis D. Hepatitis C virologic response to combined therapy with thymosin alpha-1 and interferon. *HEPATOLOGY*. 1994; 20 (Supplemental) Page 207A
21. **Sherman KE**, Lewey S, Creager R, Goodman ZD. Talc crystals in the liver of patients with chronic hepatitis C infection. *GASTROENTEROLOGY* 1995 108;A1168.
22. Lewey SM, **Sherman KE**, O'Brien J, Gutierrez A, Singleton J. Search for measles virus RNA by PCR in ileocolonic tissue samples in patients with Crohn's disease. *GASTROENTEROLOGY* 1995;108;A861.
23. **Sherman KE**, Andreatta C, O'Brien J, Gutierrez A, Harris R. Increased variability in the HCV RNA hypervariable region among patients with HCV/HIV co-infection. *HEPATOLOGY* 1995;22:A904.
24. Remotti NE, Goodman ZD, Devaney K, **Sherman KE**, Ishak KG. Autoimmune hepatitis; Clinical-pathologic features of 30 cases and comparison with hepatitis C. *HEPATOLOGY* 1995;22:A1491.
25. **Sherman KE**, Thee DL, O'Brien J. Evaluation of an immunoblot assay method for characterization of HCV genotypes. *GASTROENTEROLOGY* 1996;110:A1321.
26. Jain R, Hanto DW, **Sherman KE**, Martin SP. Bile leaks after T-tube removal from liver transplant patients: Results of endoscopic management. *HEPATOLOGY* 1996;24(pt.2) A528.
27. **Sherman KE**, Sjogren MH, Creager RL, Freeman S, Lewey S, Root S, Davis D, Weber FL, Ishak K, Goodman ZD. Thymosin alpha-1 + interferon combination therapy for chronic hepatitis C: Results of a randomized controlled trial. *HEPATOLOGY* 1996;24(pt.2) A402.
28. Manocha AP, Sossenheimer M, **Sherman KE**, Whitcomb DC, Martin SP and Ulrich CD. Ranson's criteria as a predictor of severity in patients with AIDS and acute pancreatitis. *GASTROENTEROLOGY* 1997; 112:A462.
29. Nguyen HT, **Sherman KE**. Effect of dextran on platelet function in cirrhotics with ascites.

GASTROENTEROLOGY 1997; 112:A1346.

30. **Sherman KE**, Sickler JB, Aranda-Michel J, Martin SP, Whiting JF, Weber FL, Hanto DW. Post liver transplant hepatitis C infection: A pilot trial of treatment with Rimantadine; HEPATOLOGY 1997; 118:158A.
31. **Sherman KE**, Rouster SD, Eyster ME. Quasispecies complexity and long-term outcomes in hemophiliacs with HCV/HIV coinfection; HEPATOLOGY 1997; 1127:410A.
32. Aranda-Michel J, Rouster SD, **Sherman KE**. HCV RNA Quasispecies in Patients with Normal Serum Alanine Aminotransferase (ALT) Levels. GASTROENTEROLOGY 1998;114:1205A.
33. **Sherman KE**, Sickler J, Weber FL Jr, Thee D. HCV Treatment of Interferon Non-Responders with Monthly HCV Titer Based Interferon Dose-Escalation: A Randomized Pilot Trial. HEPATOLOGY 1998; 28:282A.
34. Bejarano PA, Sherman, KE, Kohler A. Discordance Among Community and Academic Pathologists in Liver Biopsy Interpretation. GASTROENTEROLOGY 1999;116:A408.
35. **Sherman KE**, Bacon B, Feinman V, Jeffers L. Efficacy of Interferon Alfa N-3 vs. Recombinant Interferon in the Treatment of Chronic Hepatitis C Virus Infection: A Multicenter, Randomized Trial. AMERICAN COLLEGE OF GASTROENTEROLOGY 64<sup>TH</sup> ANNUAL SCIENTIFIC MEETING 1999; P464.
36. **Sherman KE**, Eyster, ME, Rouster SD, Goedert JJ. Genotype Change in Hepatitis C Virus Infected Hemophiliacs. GASTROENTEROLOGY 1999;116:A417
37. **Sherman KE**, Rouster SD, Chung R, Rajjic N. Hepatitis C prevalence in HIV-infected patients: a cross sectional analysis of the US adult clinical trials group. ANTIVIRAL THERAPY 2000 (suppl .1). 2000;5:64
38. **Sherman KE**, Sherman S, Chenier T, Tsevat T. Determination of Health Utility Measures in Patients with Chronic HCV Infection. HEPATOLOGY 2000; 32:424A
39. Zucker S, Qin X, Rouster SD, Yu F, Green RM, Feinberg J, **Sherman KE**. Mechanism of Indinavir-Induced Hyperbilirubinemia. GASTROENTEROLOGY 2001; 120:A45
40. Servoss JC, **Sherman KE**, Robbins G, Liou SH, Reisler R, Polsky B, Murphy R, Theodore D, Miskovsky E, Peters MG, Chung RT. Hepatotoxicity in the U.S. Adult AIDS Clinical Trial Group. GASTROENTEROLOGY 2001; 120:A54
41. Isler B, Aranda-Michel J, Weber FL, **Sherman KE**. Association of Heterozygote Alpha-1 Antitrypsin Deficiency with Development of End-Stage Liver Disease. GASTROENTEROLOGY 2001; 120:A565
42. Keiserman DR, Aranda-Michel J, Weber FL, **Sherman KE**. Bone Loss is Common in both Cholestatic and Non-Cholestatic End Stage Liver Disease (ESLD). GASTROENTEROLOGY 2002; 122(4):M1270

43. Keiserman DR, Both CT, deMattos AA, Remiao J, Alexandre COP, **Sherman KE**. Intrafamilial Transmission of Hepatitis C in Patients with Hepatitis C and Human Immunodeficiency Virus. *GASTROENTEROLOGY* 2002;122(4):M1456
44. Isler B, Aranda-Michel J, Weber FL, Al-Ahmadie H, Noffsinger A, **Sherman KE**. Immunohistochemistry Staining is Superior to PAS-Diastase for the Detection of Heterozygous Alpha-1 Antitrypsin Deficiency. *GASTROENTEROLOGY* 2002; 123:T844
45. Al-Ahmadie H, Saad, A, Isler B, **Sherman KE**, Noffsinger, A. The Role of Immunohistochemistry in Detecting Heterozygous Alpha1-Antitrypsin Deficiency. *THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY ANNUAL MEETING* 2002
46. Keenan ED, Rouster SD, **Sherman KE**. Complexity and Diversity of HCV RNA in African Americans. *HEPATOLOGY* 2002;36(4):A161
47. Theodore D, Bassett R, Coel M, **Sherman KE**, Glesby MJ, Chow D, Brobst SW, Alston B, Colquhoun D, Shiramizu B. Correlation of Single Photon Emission Computed Tomography (Spect) Parameters with Liver Biopsies in the Setting of HIV and HCV Co-Infection: A Multicenter Trial of The Adult AIDS Clinical Trials Group, ACTG 5096. *HEPATOLOGY* 2002;36(4):A731
48. Qin H, Rouster SD, Keenan ED, **Sherman KE**. Variable Regulation of NF-kB Signaling by HCV Core Protein. *HEPATOLOGY* 2002;36(4):A1539
49. **Sherman KE**, Shire NJ, Rouster SD, Rajjic N. Prevalence of Occult Hepatitis B Infection in HIV Infected Patients: Analysis of a Geographically Distributed ACTG Cohort. 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections 2003; Boston, MA
50. Qin H, Rouster SD, Keenan ED, Horn PS, Eyster E, Koziel M, Goedert J, **Sherman KE**. HCV RNA Quasispecies Evolution Associated with End Stage Liver Disease in a Longitudinal Cohort of HCV and HCV/HIV Infected Hemophiliacs. *GASTROENTEROLOGY* 2003;124(4):251
51. Graham CS, Wells A, Tun L, **Sherman KE**, Peters M, Chung R, Andersen J, Koziel M. The Association of Hepatitis C Virus (HCV)-Specific Immune Responses with Liver Histology in Subjects with HIV/HCV Co-Infection. *GASTROENTEROLOGY* 2003;124(4):344
52. **Sherman KE**, Horn PS, Rouster SD, Peters MG, Koziel MJ, Israel B, Chung RT. Modeling HCV Viral Kinetic Response to PEG-IFN/Ribavirin in HCV/HIV Coinfected Patients. *HEPATOLOGY* 2003;38(4):315
53. Alatrakchi N, Graham C, **Sherman KE**, Koziel MJ. Intra-hepatic CD8 T-cell Responses Towards HCV in Subjects Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus before the Anti-HCV Treatment. *HEPATOLOGY* 2003;38(4):622
54. Zander C, Andersen J, Blackard J, Lin WY, Zdunek D, Hess G, Peters M, Koziel M, **Sherman KE**, Robbins GK, Chung RT. GB Virus-C Clearance is Frequent in HIV/HCV Coinfected Patients Receiving Interferon and Ribavirin Treatment but does not Adversely Effect HIV-1



Viremia: The Adult ACTG A5071 Study Group. HEPATOLOGY 2003;38(4):1066

55. Shire NJ, Horn PS, Eyster ME, **Sherman KE**, Hemophilia HCV Study Group. Viral Kinetic Modeling in HCV Monoinfected and HCV/HIV Coinfected Hemophiliacs Treated with Pegylated Interferon and Ribavirin. 11<sup>TH</sup> Conference on Retroviruses and Opportunistic Infections 2004; San Francisco, CA.
56. **Sherman KE**, Cernhous P, Rouster SD, DaSilva B, Moseley J, Brun S. Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/R or Nelfinavir-Based Therapy. 11<sup>TH</sup> Conference on Retroviruses and Opportunistic Infections 2004; San Francisco, CA.
57. Morelli MS, Rouster SD, Giannella RA, **Sherman KE**. The Clinical Application of Polymerase Chain Reaction to Diagnose *Clostridium difficile* in Hospitalized Patients with Diarrhea. GASTROENTEROLOGY 2004;126(4)Suppl 2:T1788(page A-512)
58. Qin H, Shire NJ, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, **Sherman KE**. HCV Core Quasispecies Change is Associated with End Stage Liver Disease in a Longitudinal Cohort of HCV and HCV/HIV Infected Patients with Inherited Bleeding Disorders. GASTROENTEROLOGY 2004;126(4)Suppl 2:M2017(page A-741)
59. **Sherman KE**, Shire NJ, Rouster SD, Dericks SD, Steinberg JP, Leissing C, Eyster ME. HCV Quasispecies Association with Early Treatment Response in Singly and Coinfected Patients with Inherited Bleeding Disorders. GASTROENTEROLOGY 2004;126(4)Suppl 2:81(page A-665)
60. Shire NJ, **Sherman KE**, Horn PS, Eyster EM and the Hemophilia HCV Study Group. Viral Kinetic Parameters and Treatment Response in HIV/HCV Coinfected vs. HCV Infected Hemophiliacs. 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA February 2005.
61. Mann E, Stanford S, **Sherman KE**. Assessment of mutations in hepatitis C virus (HCV) core protein associated with progression to end-stage liver disease. GASTROENTEROL 2005 April; 128(4) Suppl 2:M963 (page A-748).
62. O'Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, **Sherman KE**, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown NA. Randomized trial of valopicitabine (NM283), alone or with peg-interferon vs. retreatment with peg-interferon plus Ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: First interim results. HEPATOLOGY 2005 October; 42(4) Suppl 1:95 (page 234A).
63. **Sherman KE**. High frequency of anemia in HCV-HIV coinfecting persons receiving weight-based Ribavirin and Zidovudine. HEPATOLOGY 2005 October; 42(4) Suppl 1: 1230 (page 681A).
64. Gitlin N, Manns M, **Sherman KE**, Berg T, Pockros P, Hezode C, Roberts S, Zeuzem S. Week 4 virological response with peginterferon alfa-2a (40KD) (PEGASYS) plus Ribavirin (RBV, COPEGUS) portends a sustained virological response (SVR) after 24 weeks in genotype 1 chronic hepatitis C patients with persistently normal ALT activity. HEPATOLOGY 2005

October; 42(4) Suppl 1:1238 (page 685A).

65. Shire NJ, Rouster S, Dericks S, Fichtenbaum C, **Sherman KE**. Occult hepatitis B virus in an HIV-infected cohort. 13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Denver, CO February 2006.
66. Pockros P, O'Brien, Godofsky E, Rodgriguez-Torres M, Afdhal N, Pappas SC, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, **Sherman KE**, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N. Valopicitabine (NM283), alone or with PEG-interferon, compared to PEG-interferon/Ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to pegIFN/RBV: Week 24 results. GASTROENTEROL 2006 April; 130(4) Suppl 2: 4 (page A748).
67. **Sherman KE**, Goodman ZD, Sullivan ST, Faris-Young S. Diagnostic liver biopsy in patients with advanced fibrosis and cirrhosis. GASTROENTEROL 2006 April; 130(4) Suppl 2: 554 (page A770).
68. Atiq M, Sherman SN, **Sherman KE**. Impact of alcohol dependence on the health values of patients with HCV. GASTROENTEROL 2006 April; 130(4) Suppl 2: T1045 (page A462).
69. Shire NJ, Rouster SD, Stanford SD, **Sherman KE**. High Prevalence of Mixed HBV Genotypes in Patients with HIV. 12<sup>th</sup> International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Paris France July 2006.
70. Franco K, Shire N, Riddle T, Sheppard H, Goedert J, **Sherman KE**, Nelson J. HCV Infection is Associated with Decreased Co-receptor Switching and Increased Viral Diversity of HIV-1 in Co-infected Subjects. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA February 2007.
71. Shire N, Rao M, Andersen J, Butt A, Chung R, **Sherman KE**, and The ACTG 5178 Study Group. Improving Non-invasive Discrimination of Fibrosis Stage in HIV/HCV-co-infected Patients. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA February 2007.
72. Coffin S, Berg C, Dove L, Poordad F, Curry M, Regenstein F, **Sherman KE**, Roland M, Stock P, Terrault N. Survival and Risk of Hepatitis B Virus (HBV) Recurrence in HIV-HBV Coinfected Liver Transplant Recipients: Preliminary Findings From The HIV-TR Study. HEPATOLOGY 2007 October; 46(4) Suppl 1:28 (page 245A).
73. **Sherman KE**, Gordon S, Iftikar R, Rodriguez-Torres M, Rustgi V, Di Bisceglie A. Retreatment Of Treatment Experienced HCV Patients with Pegylated Interferon Alfa-2A and Thymosin Alpha-1: Pooled Analysis of Two Randomized Controlled Trials. HEPATOLOGY 2007 October, 46(4) Suppl 1:1331 (page 830A).
74. **Sherman KE**, Andersen J, Butt A, Goodman Z, Umbleja T, Alston B, Koziel M, Peters M, Sulkowski M, Chung R and ACTG A5178 Study Team. Sustained Long-Term Antiviral Maintenance with Pegylated Interferon in HCV/HIV co-infected Patients: Early Viral Response and Effect on Fibrosis in Treated and Control Subjects. 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Boston, MA February 2008

75. Martin C, Shire N, Rouster S, Shata T, **Sherman KE**, Blackard J. Identification of HBV Pre-surface and Surface Mutations among HIV+ Individuals with Occult HBV Infection. 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA February 2008
76. Ma G, Barrett A, **Sherman KE**, Shata T, Blackard J. Detection of HIV in Liver Biopsies and Intrahepatic Lymphocytes. 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Boston, MA February 2008
77. Peters M, Andersen J, **Sherman KE**, Chung R, Graham C, Koziel M, and ACTG 5071 Team. Severity of Liver Disease Associated with IL-10 DNA Polymorphisms in Patients Co-infected with HIV and HCV. 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Boston, MA February 2008
78. Zamor P, Shire N, Rouster S, Eyster E, **Sherman KE**. Utility and Predictors of Rapid Viral Responses in HCV and HCV/HIV Co-infected Hemophiliacs. 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Boston, MA February 2008
79. Poordad F, Shiffman M, **Sherman KE**, Smith J, Yao M, George S, Adda N, McHutchinson J for the Vertex Study Group. A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results. 43<sup>rd</sup> Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008.
80. Chung R, Umbleja T, Butt A, Goodman Z, Andersen J, Koziel M, Alston B, Peters M, Sulkowski M, **Sherman KE** & ACTG 5178 Team. SLAM-C (ACTG A5178): Role of Early Virologic Response in Extended Therapy with PEG-Interferon and Weight-Based Ribavirin in HCV/HIV Co-infection. 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 2009
81. Zamor P, Rouster S, **Sherman KE**. Hepatic Apoptosis in HCV and HCV/HIV Co-infected Subjects. 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 2009
82. Martin C, Welge J, Shire N, Rouster S, Shata T, **Sherman KE**, Blackard J. Occult HBV Infection is Associated with Decreased Levels of Soluble Fas Antigen in HIV-infected Patients. 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 2009
83. **Sherman KE**, Rouster S, Feinberg J, Bini E, Blackard J, Shata T. Hepatic Apoptosis following Initiation of ART in HCV/HIV co-infected Subjects. 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 2009
84. Rashkin S, Rouster S, **Sherman KE**. 751 CD4 Counts in HCV Monoinfected Patients: Relationship to Fibrosis and Pegylated Interferon. *GASTROENTEROLOGY* 2009 May (Vol. 136, Issue 5 (page A-807))
85. Blackard J, Ma G, Rouster S, Martin C, Shata T, **Sherman KE**. Baseline hepatitis C virus variability does not predict flares in HIV/HCV co-infected persons initiating antiretroviral therapy. 5th International Workshop on HIV and Hepatitis Co-infection, Lisbon, Portugal, June

2009.

86. Blackard J, Ma G, Rouster S, Barrett A, Shata T, **Sherman KE**. HIV is frequently detected in liver biopsy tissue. 5th International Workshop on HIV and Hepatitis Co-infection, Lisbon, Portugal, June 2009.
87. Terrault N, Barin B, Schiano T, Poordad F, Wong M, DeVera M, Simon D, Rosenthal L, Jayaweera D, Johnson L, Olthoff K, Stosor V, **Sherman KE**, Eghtesad B, Harland R, Regenstein F, Hamilton J, Pruett T, Roland M, Stock P. Survival and Risk of Severe Hepatitis C Virus (HCV) Recurrence in Liver Transplant (LT) Recipients Coinfected with Human Immunodeficiency Virus (HIV) and HCV. *HEPATOLOGY* 2009 October; 50(4) Suppl 195 (page 396A).
88. Kaiser T, **Sherman KE**, Eckman M. Simulation Modeling of the Natural History of Hepatitis B Progression in a United States Adult Population – Determining Life Expectancies. *HEPATOLOGY* 2009 October; 50(4) Suppl 420 (page 504A).
89. Zamor P, Blackard J, Martin C, **Sherman KE**. HCV Viral Evolution in HCV/HIV Coinfected Subjects after Initiation of HAART. *HEPATOLOGY* 2009 October; 50(4) Suppl 788 (page 673A).
90. Schmeltzer P, Rouster S, **Sherman KE**. Prevalence of Occult Hepatitis B Among Anti-Hepatitis B Core Positive Blood Donors. *HEPATOLOGY* 2009 October; 50(4) Suppl 1497 (page 993A).
91. Butt A, Umbleja T, Andersen J, **Sherman KE**, Chung R. Incidence and Predictors of Anemia in HCV/HIV Co-infected Subjects Treated with Pegylated Interferon and Ribavirin in A5178. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2010.
92. Shata MT, Bartholomew KA, Rouster SD, Blackard JT, Sterling RK, Bini E, Perelson AS, Goodman ZD and **Sherman KE**. Strong HCV and HIV Immune Responses in Co-Infected Subjects Who Experienced ALT Flare and/or Rebound HCV Viral Load after ART Initiation. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2010.
93. Blackard J, Welge J, Taylor L, Mayer K, Klein R, Celentano D, Schuman P, Jamieson D, Gardner L, **Sherman KE**. HIV Mono-infection Is Associated with a Non-invasive Index of Liver Fibrosis in Women. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2010.
94. Ragni M, DeVera M, Roland M, Wong M, Stosor V, **Sherman KE**, Hardy D, Blumberg E, Barin B, Stock P. Outcomes in HIV/HCV Hemophilic vs Non-hemophilic Transplant Candidates. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2010.
95. **Sherman KE**, Rouster SD, Feinberg J, Blackard J, Sterling R, Goodman ZD, and Shata MT. Soluble CD14 is associated with HIV viral load, ALT, and fibrosis in HCV/HIV coinfecting subjects. 61st American Association for the Study of Liver Diseases Conference. October 29-November 2, 2010. Boston, MA. *HEPATOLOGY* 2010; 52(4 suppl) 794A, p180A.

96. Zamor PJ, Rouster SD, **Sherman KE**. HCV NS3 Mutations in HCV-HIV coinfecting and HCV monoinfected subjects. 61st American Association for the Study of Liver Diseases Conference. October 29-November 2, 2010. Boston, MA. HEPATOLOGY 2010; 52(4 suppl) 733A, p172A.
97. Blackard JT, Ma G, Rouster SD, Martin CM, Shata MT, and **Sherman KE**. 6th International HIV and Hepatitis Co-Infection Workshop. May 31-June 2, 2010. Tel Aviv, Israel. Abstract 0-10: Hepatitis C virus (HCV) diversity in the liver and plasma of HIV/HCV co-infected persons.
98. Kemmer N, Hua L, Anderson J, Chung R, Butt A, **Sherman K** for the ACTG 5178 Team. Health Related Quality of Life in Subjects with HCV/HIV Coinfection: Results of the SLAM-C Study. Conference on Retrovirus and Opportunistic Infections, Boston, MA. February 2011
99. Gavart S, **Sherman KE**, Thal G, Nuyts G, McAllister S, Beumont M, Luo D, Adda N, Wright C, Muir AJ. 46<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver (EASL). Impact of Telaprevir-Based Treatment Regimens on Fatigue in Genotype 1 HCV Treatment-Naïve Patients: Results from Advance and Illuminate Studies. HEPATOLOGY 2011 Mar, 54 Suppl (1), 477.
100. Martin CM, Rouster SD, Shata MT, **Sherman KE**, and Blackard JT. Occult hepatitis B virus mutations result in decreased HBsAg expression in vitro. American Society for Virology Annual Meeting, Minneapolis, MN. July 2011 (Abstract 452)
101. Blackard JT, Ma G, Martin C, He Y, Shata MT, and **Sherman KE**. Replication efficiency of the non-structural 5B (NS5B) protein is increased after initiation of antiretroviral therapy in HIV/HCV co-infected patients. 18<sup>th</sup> International Symposium on Hepatitis C Virus and Related Viruses, Seattle, WA. September 2011
102. **Sherman KE**, Sulkowski MS, Zoulim F, Alberti A, Wei LJ, Sullivan J, Martin EC, Kieffer TL, De Meyer S, Picchio G, Graham CS, Zeuzem S. Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-based Regimens: Interim Analysis of the EXTEND Study. HEPATOLOGY 2011 October; 54(4) Suppl S1, 248 (page 124A).
103. **Sherman KE**, Rockstroh JK, Dieterich DT, Soriano V, Girard P-M, McCallister S, Adda N, Adiwijaya BS, Mahnke L, Sulkowski MS. Telaprevir Combination with Peginterferon Alfa-2A/Ribavirin in HCV/HIV Coinfected Patients: 24-Week Treatment Interim Analysis. HEPATOLOGY 2011 October; 54(4) Suppl S1, LB-8 (page 300A).
104. Bartels DJ, De Meyer S, Sullivan J, Dierynck I, Adda N, Kauffman RS, Jacobson IM, **Sherman KE**, Zeuzem S, Kwong AD, Picchio G, Kieffer TL. Summary of Clinical Virology Findings from Clinical Trials of Telaprevir. HEPATOLOGY 2011 October; 54(4) Suppl S1, 1328 (page 984A).
105. Lin MV, Rouster SD, Charlton AN, **Sherman KE**. High Resolution Melting Analysis: A Rapid and Accurate Alternative Method for the Detection of IL28B Single-Nucleotide Polymorphism. 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI), March 5-8, 2012. Seattle, Washington. CROI Program & Abstracts, March 2012; 770A, page 369.

106. Sulkowski MS, **Sherman KE**, Soriano V, Rockstroh J, Dieterich DT, Girard PM, Bsharat M, Henshaw J, Rubin RA, Garg V, Adda N. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. 63<sup>rd</sup> American Association for the Study of Liver Diseases Conference. November 9-13, 2012. Boston, MA. HEPATOLOGY 2012 October; 56 Suppl 1(Pages 219A)
107. Eckman MH, Gordon SC, Talal A, Schiff ER, **Sherman KE**. Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States. 63<sup>rd</sup> American Association for the Study of Liver Diseases Conference. November 9-13, 2012. Boston, MA. HEPATOLOGY 2012 October; 56 Suppl 1(Pages 261A).
108. Lin MV, Rouster SD, **Sherman KE**. High Resolution Melting (HRM) Analysis for the Detection of IL28B rs12979860 SNP. 63<sup>rd</sup> American Association for the Study of Liver Diseases Conference. November 9-13, 2012. Boston, MA. HEPATOLOGY 2012 October; 56 Suppl 1(page 673A).
109. Barnard RJ, Howe AY, Hazuda D, Burroughs M, Zeuzem S, **Sherman KE**. Analysis of Resistance Associated Amino acids (RAVs) in patients enrolled in the anemia management study for Boceprevir (BOC) plus Pegylated interferon and ribavirin. 63<sup>rd</sup> American Association for the Study of Liver Diseases Conference. November 9-13, 2012. Boston, MA. HEPATOLOGY 2012 October; 56 Suppl 1(page 718A-719A).
110. Jennings CL, **Sherman KE**. Acute HCV Infection in Young Adults. 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-7, 2013. Atlanta, Georgia. CROI Program & Abstracts, March 2013; P-208.
111. M.W. Fried, K.R. Reddy, A.M. Di Bisceglie, D.M. Jensen, I.M. Jacobson, M.S. Sulkowski, N.A. Terrault, N.H. Afdhal, S.C. Gordon, P.J. Pockros, P.Y. Kwo, G.T. Everson, **K.E. Sherman**, A.J. Muir, B.L. Pearlman, T.G. Stewart, M. Vainorius, J.A. Peter, D.R. Nelson, for HCV-Target. 818 HCV-Target a Longitudinal, Observational Study of North American Patients with Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir. 48th Annual meeting of the European Association for the Study of the Liver. April 24-28, 2013. Amsterdam, Netherlands. HEPATOLOGY Volume 58, Supplement 1, April 2013, Pages S335
112. Lin MV; Rouster SD; Charlton AN; **Sherman KE**. Comparison of HCV NS3 Mutations Between Hemophiliacs and Non-Hemophiliacs Infected With HCV or HCV/HIV. Digestive Disease Week May 18-21, 2013. Orlando, FL. GASTROENTEROLOGY Volume 144, Issue 5, Page S449
113. Butt AA, Chew KW, Corey K, Chung RT, Butler J, **Sherman KE**, Freiberg MS, Erqou S. HCV Viremia and the Risk of Acute Myocardial Infarction at Various Lipid Levels. Annual Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014. Boston, Massachusetts. CROI Program & Abstracts, 685A, page 441.
114. Butt AA, Yan P, Re VL, Klein MB, Goetz MB, Leaf D, Freiberg MS, **Sherman KE**. Liver Fibrosis Progression Among Persons With Recently Acquired HCV Infection. Annual Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014. Boston, Massachusetts. CROI Program & Abstracts, 649A, page 420.

115. Baum MK, **Sherman KE**, Martinez SS, Greer P, Stewart T, Jacobs C, Luisi S, Dizon K, Campa A. Microbial Translocation, Immune Activation, Apoptosis and Liver Fibrosis in the MASH Cohort. Annual Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014. Boston, Massachusetts. CROI Program & Abstracts, 788A, page 507.
116. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, **Sherman KE**, Liu,Z, Noviello S, Ackerman P. Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection:ALLY-2 Study. Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015. Seattle, Washington. CROI Program & Abstracts, 151LB, page 171.
117. Razeghi SD, Rouster SD, **Sherman KE**. Prevalence of HDV in a Midwestern HIV-HBV Coinfected Population. Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015. Seattle, Washington. CROI Program & Abstracts, 707A, page 55.
118. Abdel-hameed EA, Rouster SD, Zhang Xiang, Chen J, Medvedovic, **Sherman KE**. HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin. Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015. Seattle, Washington. CROI Program & Abstracts, 698A, page 55.
119. **Sherman KE**, Ke R, Rouster SD, Perelson AS. Viral Kinetic Profiles of HCV Response to Telaprevir-Based Therapy in Patients with Hemophilia. Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015. Seattle, Washington. CROI Program & Abstracts, 690A, page 54.
120. **Sherman KE**, Kong L, Blackard JT. Inhibition of HCV Replication by CCR5 Blockade with Cenicriviroc and Maraviroc. 50th International Liver Congress 2015 European Association for the Study of the Liver (EASL), April 22-26, 2015. Vienna, Austria. Journal of Hepatology Volume 62, supplement 2, page S684, P0906.
121. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, **Sherman KE**, Liu,S, Noviello S, Ackerman P. Daclatasvir plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study. 50th International Liver Congress 2015 European Association for the Study of the Liver (EASL), April 22-26, 2015. Vienna, Austria. Journal of Hepatology Volume 62, supplement 2, page S263, LP01.
122. Abdel-hameed EA, Rouster SD, Ji H, Ulm A, Hetta H, **Sherman KE**, Shata MT. Evaluation of the Role of the Immune Responses in Determining the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor (PI) Therapy. Digestive Diseases Week (DDW) 2015, Washington, DC, May 16-19, 2015.Gastroenterology, Vol. 148, Issue 4, S-1095.
123. **Sherman KE**, Abdel-Hameed EA, and Rouster SD. CCR2/CCR5 Antagonism with Cenicriviroc Decreases Fibrosis Scores in HIV-Infected Patients. HEP DART 2015, December 6-10, 2015 Grand Wailea Wailea, Hawaii.
124. Abdel-hameed EA, Rouster SD, **Sherman KE**. Assessment of Hepatic Antifibrotic Effect of Cenicriviroc in Patients With HIV. CROI 2016, February, 2016, Boston,MA.

125. **Sherman KE**, Rouster SD, L Kong, MT Shata, T Archampong, A Kwara, JT Blackard. Zika Virus in an HIV-infected Cohort in Ghana. Emory Special Conference: Bridging The Sciences: Zika Virus. May 2, 2016, Atlanta, GA.
126. Enass A. Abdel-hameed, Norah Shire, Li Yu, Susan D. Rouster, Mohamed Tarek M. Shata, **Sherman KE**. Occult HBV is associated with lower levels of apoptotic markers compared to non-occult HBV. HIV & Liver Disease, September, 2016; Jackson Hole, WY.
127. Enass A. Abdel-hameed, Susan D. Rouster, Mohamed Tarek Shata, **Sherman KE**. Enhanced liver fibrosis (ELF) index correlates with serum pro-inflammatory cytokines/ chemokines in HIV patients treated with Cenicriviroc. HIV & Liver Disease, September, 2016; Jackson Hole, WY.
128. P. Safaie, E. Abdel-Hameed, S. Rouster, **Sherman KE**. CCR5-Δ32 mutation is associated with decreased fibrotic progression markers in HCV/HIV infected subjects. HIV & Liver Disease, September, 2016; Jackson Hole, WY.
129. EA Abdel-Hameed. SD Rouster, MM Shata, **Sherman KE**. Association of T-Cell Exhaustion Markers, PD1, TIM3 and LAG3 with Liver Cirrhosis, and Responses to Therapy in Chronic HCV Infected Patients. AASLD, The Liver Meeting 2016; Boston MA, November 2016.
130. **Sherman KE**, SD Rouster, MT Shata, N Terrault, JT Blackard, S Kottlil. Prevalence of Hepatitis E Virus Infection in HCV and HCV/HIV Coinfected Patients. AASLD, The Liver Meeting 2016; Boston MA, November 2016.
131. **Sherman KE**, Boyce CL, Rouster SD, Barin B, Terrault N, Kottlil S, Blackard JT, Shata MT. Longitudinal Analysis of Hepatitis E Virus (HEV) in a U.S. Cohort of HIV-Infected Liver and Kidney Transplant Recipients. AASLD, Washington, DC, October 2017
132. Martinez S, **Sherman KE**, A Campa, Rouster SD, Seminario L, Liu Q, Hernandez J, Mukesh M, Khalsa J, Baum MK. The Interrelationships between PNPLA3 Variants, BMI, Liver-Related Apoptosis and Oxidative Stress in HIV+ Adults from the (Miami Adults Studies in HIV) MASH Cohort. AASLD, Washington, DC, October 2017
133. **Kenneth E. Sherman**, Enass A. Abdel-Hameed, Susan D. Rouster, Norah Terrault, Jason T. Blackard, Mohamed T. Shata, Shyam Kottlil. Hepatitis E avidity in a cohort of hepatitis C and hepatitis C/human immunodeficiency virus infected patients. ILC2017-RS-3721. EASL
134. Kristen M. Marks, Nwora L. Okeke, Lawrence Park, Cody A. Chastain, Kimberly Workowski, Chris Woods, **Kenneth E. Sherman**, Gregory K. Robbins, Stefan Mauss, Jürgen K. Rockstroh, Susanna Naggie. Abstract Number: 604. Multicenter Registry in HIV/HCV Co-Infected Patients Initiating Ledipasvir/Sofosbuvir. CROI, Boston MA, March 2018.
135. Marianna K. Baum, Sabrina S. Martinez, Richard L. Ehman, **Kenneth E. Sherman**, Pedro J. Greer, Jun Chen, Robert Laird, Angela Laird, Leslie Seminario, Angelique Johnson, Alhanooof Alohaly, Mukesh Mudgal, Alicia Sneij, Javier Tamargo, Adriana Campa. Abstract Number: 648. MR Elastography Detects Higher Liver Fibrosis in Uncontrolled HIV Infection. CROI, Boston MA, March 2018.



136. **Sherman, Kenneth E. et al.** Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia. *Gastroenterology*, Volume 154, Issue 3, 453 – 456. DDW, Chicago, IL, May 2017.
137. Parham Safaie, Isaac Privitera, **Kenneth E. Sherman**. Underutilization of Hepatitis D Virus Testing Among HBV Monoinfected and HBV/HIV Coinfected Patients. *Gastroenterology*, Vol. 152, Issue 5, S162 DDW, Chicago, IL, May 2017
138. Ke-Qin Hu, Wei Cui, Susan D. Rouster, **Kenneth E. Sherman**. Hepatitis C Virus Antigens Enzyme Immunoassay (HCV-AGS EIA) for One-Step Diagnosis of Viremic HCV Co-Infection in HIV Infected Individuals. *Gastroenterology*, Vol. 152, Issue 5, S1078. DDW, Chicago, IL, May 2017
139. Baum M, Zarini G, Ehman R, et al., MR elastography detects higher liver fibrosis in HIV infected cocaine users in the Miami Adult Studies on HIV (MASH) Cohort. *Hepatology*. Volume 68 Supplement 1 Pages 618A – 618A Meeting Abstract. 1060 Published. OCT 2018
140. Martinez S, Campa A, **Sherman KE**, et al. Higher liver fibrosis and iron status with magnetic resonance elastography in HIV. *Hepatology* Volume 68 Supplement 1 Pages 619A - 620A Meeting Abstract. 1063 Published. OCT 2018.
141. **Sherman KE**, Rouster SD, Kong LX et al. Zika virus replication in hepatocyte cell lines. *Hepatology* Volume 68 Supplement 1 Pages. 713A -714A Meeting Abstract 1229 Published OCT 2018
142. Sulkowki M, moon J, **Sherman KE**, Darling J, Muir A, Khalili M, Fishbein D, Hineostroza F, Shiffman M, DiBisceglie A. The PRIORITIZE study: A Pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders. *Journal of Hepatology* Volume 70 Issue 1, PagesE242-E242, Supplement 1, Meeting Abstract THU-182. Published APR 2019.
143. Abdel-Hameed EA, Rouster SD, Jennings CL, Anwar N, Shata MTM, **Sherman KE**. Reversal of Immune Exhaustion Following SVR in Chronic HCV Patients. *Gastroenterology*, Volume 156, Issue 6, Pages S10511-S1051, Supplement 1, Meeting Abstract TU1543. Published MAY 2019.
144. Shata MT, Abdel-Hameed E, Rouster SD, Kottiril S, **Sherman KE**. The Effect of Coinfection with HCV And/Or HIV on the Sensitivity and Specificity of HEV ELISA. *Hepatology* Volume 70, Pages 639A-640A, Supplement 1, Meeting Abstract 1056. Published OCT 2019.
145. Butt A, Yan P, Aslam S, **Sherman KE**, Siraj D, Safdar N, Hameed B. HCV/HBV Coinfection and the Risk of Fibrosis Progression, Hepatic Decompensation and Mortality in the Erchives Cohort. *Hepatology* Volume70, Pages 587A-588A, Supplement 1, Meeting Abstract 960. Published OCT 2019.
146. Butt A, Yan P, Aslam S, **Sherman KE**, Siraj D, Safdar N, Hameed B. SVR Rates Are comparable or higher in HCV/HBV Coinfected Persons Compared to HCV Monoinfected Persons Treated with Directly Acting Antiviral Agents: Results from Erchives. *Hepatology* Volume 70, Pages 943A-943A, Supplement 1, Meeting Abstract 1564. Published Oct 2019.

147. Bari K, **Sherman KE**, Kaiser TE, Anwar N, Cohen RM, Kleesattel D, Shah SA. Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Prospective Phase 2 Pilot Study. *Hepatology* Volume 70, Pages 142A-142A, Supplement 1, Meeting Abstract 218. Published Nov 2019.
148. **Sherman, KE**(Sherman, Kenneth E.) Rouster, SD(Rouster, Susan D.) Gersch, J(Gersch, Jeffrey)Cloherty, GA(Cloherty, Gavin A.). Assessment and Validation of HBV Pre-Genomic RNA Assays. *Gastroenterology* Volume:158, Issue 6, Page S1315-S1316, Supplement 1, Meeting Abstract Sa1509. Published May 2020
149. Jennings, CL (Jennings, Carrie L.) **Sherman, KE** (Sherman, Kenneth E.). Low Rates of Vaccine Response to Hepatitis B Vaccination but not Hepatitis A Vaccination in HIV/HCV Coinfected Persons. *Gastroenterology* Volume 158, Issue 6, Page S1274-S1274, Supplement 1 Meeting Abstract 383. Published May 2020.
150. Farooq, PD(Farooq, Priya D.) Gray, M(Gray, Meagan) Kaiser, TE(Kaiser, Tiffany E.) **Sherman, KE**(Sherman, Kenneth E.). Vaccination of Liver Transplant Candidates is Suboptimal Prior to Transplant. *Gastroenterology* Volume 158, Issue 6, Page S1318-S131, Supplement 1 Meeting Abstract Sa1518. Published May 2020.
151. Portocarrero-Castillo, A(Portocarrero-Castillo, Andrea), Patel, ND(Patel, Neil D.), Li, LZ(Li, Lezhi), Christianson, AL(Christianson, Annette L.), Meganathan, K(Meganathan, Karthikeyan), Fontana, RJ(Fontana, Robert J.), **Sherman, KE**(Sherman, Kenneth E.), Ni, YZ(Ni, Yizhao), Yeboah-Korang, A(Yeboah-Korang, Amoah). Risk of Idiosyncratic Drug-Induced Liver Injury Among Patients with Prior History of Drug Allergy. *American Journal of Gastroenterology*. Volume 115, Page S561-S561, Supplement S, Meeting Abstract S1113. Published Oct 2020
152. Abdel-Hameed, E(Abel-Hameed, Enass), Rouster, SD(Rouster, Susan D.), Shata, MT(Shata, Mohamed Tarek), **Sherman, KE**(Sherman, Kenneth E.). CCR5 Delta-32 Associates with Changes in Regulatory T-Lymphocyte Markers of Activation and Migration in HIV/HCV Patients. *Hepatology*. Volume 72, Page 253A-253A, Supplement 1, Meeting Abstract 401. Published Nov 2020
153. Sprague, E(Sprague, Elizabeth), Sharma, Y(Sharma, Yeshika), **Sherman, KE**(Sherman, Kenneth E.), Shah, SA(Shah, Shimul A.), Gregory, DL(Gregory, Dyanna L.), VanWagner, LB(VanWagner, Lisa B.), Yeboah-Korang, A(Yeboah-Korang, Amoah). Cardiovascular Risk of Orthotopic Liver Transplantation (CAR-OLT) Scores and Adverse Cardiac Events in Liver Transplant Recipients at a Single Institution. *Gastroenterology*. Volume 160, Issue 6, Page S781-S781, Supplement S, Meeting Abstract 446. Published May 2021
154. **Sherman, KE**(Sherman, Kenneth E.), Rouster, SD(Rouster, Susan D.), Meeds, HL(Meeds, Heidi L.), Abdel-Hameed, E(Abel-Hameed, Enass), Jennings, C(Jennings, Carrie), Daria, D(Daria, Diane), Stambrook, E(Stambrook, Elizabeth), Shata, MT(Shata, Mohamed Tarek). SARS-COV-2 Vaccine Responses in Subjects with Liver Disease or Immunosuppressed Solid Organ Transplant Recipients. *Hepatology*. Volume 74, Page 337A-337A, Supplement 1, Meeting Abstract 550. Published Oct 2021

## **Narrative Report**

### **Clinical:**

As a clinician with board certification in Internal Medicine (1988) and Gastroenterology (1991), I have served as an attending physician and consultant at the University of Cincinnati Medical Center since 1994. My primary role is as a hepatologist, including transplant hepatology. As a clinical leader, I served as the director of hepatology from 1998 till 2004. During a subset of this period I was recognized as the UNOS certified Medical Director of Liver Transplantation. Since 2003, I served as the Director/Chief of the Division of Digestive Diseases which incorporates all Gastroenterology, Hepatology and Endoscopy functions within the medical center. I have grown the GI faculty in the division from 7 in 2003 to nearly 30 in 2022. I have served in numerous advisory and leadership capacities within the Department of Medicine, the University and within the Medical Center.

### **Education:**

I have been actively involved in the training and mentorship of numerous residents, fellows, medical students and undergraduates during my time in both Colorado and Cincinnati. Many of my trainees have gone on to successful academic careers and positions of leadership in the pharmaceutical industry. Furthermore, I have provided encouragement and guidance to a host of young investigators in the field of HIV-associated liver disease at institutions throughout the U.S. and many have now emerged as independent leaders in the field. I have taught a third-year medical student small group session on Acute and Viral Hepatitis for the last 23 years, and have routinely provided lectures in the medical school for both 1<sup>st</sup> and second year students on topics of liver disease. I served as the Gastroenterology fellowship program director for 9 years, maintaining ACGME accreditation. During that time period I expanded the fellowship from a 2-year training program with 2 fellows/year to a 3 year program with 3-4 fellows/year, prior to the ABIM mandate to do so. I served on the AGA Manpower and Training committee and worked on the re-development of the curriculum for Hepatology among the joint GI Societies (AGA, AASLD, ACG, ASGE), representing the AGA in this area. I also provided the initial leadership and proposals which led to the AGA-sponsored Gastroenterology In-service examination for trainees which is now utilized by programs throughout the United States.

### **Research:**

I have led a VA and/or NIH funded research group at the University of Cincinnati College of Medicine since 1996. My research primarily involves viral hepatitis epidemiology, natural history, immunopathogenesis, diagnostics and treatment. Within that broad expanse, I have focused on liver disease in the HIV-infected person, using varying levels of the immunosuppressed state to address key questions about disease progression and outcomes. The Hepatitis Research Group (HRG) which I created has answered key questions related to the relationship of hepatitis B, C and E to disease progression and treatment response in those with HIV infection, which have influenced guidelines and clinical care.

#### *Hepatitis C and HIV*

With the development of combination antiretroviral therapies (cART) in 1996, HIV was converted from a rapidly progressive and highly morbid disease process to a more chronic disease state. By the mid-1990s, it became clear that the cause of death in those living with HIV was changing, and liver disease was emerging as a leading cause of both morbidity and mortality among patients who had access to cART. The reasons for this were unclear, but it appeared that the newly described hepatitis C virus (HCV) was an important factor in this epidemiologic shift. Early work in Colorado (Journal of Infectious Diseases, 1991, J Clin Micro, 1993), and later with the Multicenter Hemophilia Cohort Study (J Infectious Diseases, 1999 and 2001) and the AIDS Clinical Trials group (Clinical Infectious Diseases,

2002) made several significant contributions including providing the first reports of HCV prevalence in HIV patients and the first report describing higher HCV viral loads in this immunosuppressed population. We described the relationship between quasispecies complexity and disease outcomes including progression and treatment response (Blood, 2002, 2005). Dr. Sherman was a key player in the use of mathematical models to characterize treatment of HCV and to lead studies that established the paradigm of response guided therapy in both HCV and HCV/HIV infected patients.(Gastroenterology, 2005, New England Journal of Medicine, 2011).

The relationship between HCV infection and the initiation of antiretroviral therapy was particularly intriguing. Using previously established HIV treatment cohorts within the ACTG, and in collaboration with Ray Chung, MD we noted that ALT flares were commonly observed following the start of cART, particularly among those with low CD4 counts (AIDS, 2002). Our group then studied the relationship of cART initiation and changes in both ALT (a marker of liver injury) and HCV viral replication using samples collected during the Phase 3 trial for lopinavir/ritonavir. This allowed us to better characterize the outcomes in a more controlled manner. cART initiation was associated with an increase in HCV viral loads, which is paradoxical because patients rapidly increased CD4 counts and improved overall immune status (Clinical Infectious Diseases, 2005). Detailed examination of this process required development of a small, rigorously evaluated cohort of HCV/HIV coinfecting patients starting HIV. Among key findings was that following cART administration, HIV viral load declined rapidly. The loss of both HIV and its soluble gp120 proteins led to a downregulation of interferon-stimulated gene products (ISGs) which released HCV replication. This was accompanied by the reconstitution of HCV specific T-cell responses which re-established a new setpoint for HCV replication following acute ALT flare (Science Translational Medicine, 2014).

The morbidity and mortality of HCV/HIV coinfection is primarily associated with rapid progression of liver disease. Within the ACTG I led a multicenter trial (SLAM-C) utilizing interferon-based therapies to try and modulate hepatic fibrosis which underlies the progression of liver disease to a cirrhotic and decompensated state (J AIDS, 2010). Working with Shyam Kottlil, MD, PhD (then at the NIH), we postulated that rapid progression was due to a combination of factors which were in part modulated by CCR5 on the hepatocytes and stellate cells of the liver. CCR5 engages gp120 and HIV-1 virions leading to downstream effects on cytokine display. We examined this in two large cohorts, namely the Multicenter Hemophilia Cohort Study and a Phase 2 trial of a dual CCR5/CCR2 antagonist. Our recently published work suggests that CCR5 receptor blockade or mutation (CCR5 delta-32) has a significant effect on progression of hepatic fibrosis among patients with HCV/HIV coinfection (Clinical Infectious Diseases, 2018). CCR5 blockade also appears to directly modulate HCV replication (PLoS One, 2019)

I have also played a key role in the development of cost-effectiveness models related to HCV that have influence public policy. Starting with models of ALT screening of blood donors (NEJM, 1982) I have participated in multiple sequential analyses of interventions and treatments. In collaboration with Mark Eckman, MD we have published models of HCV screening (Clinical Infectious Diseases, 2013), use of HCV infected organ in kidney transplantation (Annals of Internal Medicine, 2018) and evidence to support universal HCV screening in adults (Clinical Gastroenterology & Hepatology, 2019).

#### Hepatitis B and HIV

The hepatitis B virus (HBV) is also a potent modulator of hepatic fibrosis and liver injury in those with HIV infection. Early work involved description of HBV flare associated with lamivudine withdrawal or resistance associated viral breakthrough (Clinical Infect Diseases, 1999) Our group first described the frequency of occult and HBsAg positive HBV infection among those with HIV, using a scientifically weighted sample from the ACTG to provide an estimation of the disease burden in the U.S.(J AIDS,

2004). We have extensively evaluated the mechanisms underlying occult HBV which is common in those with HIV and relatively uncommon in immunocompetent hosts. It is possible that occult HBV represents a persistent transitional state in those with HIV who are unable to fully clear infection. Recent studies by our group have focused on the role of PD-1 immune exhaustion markers in those with and without HIV infection. Hepatitis B prevention among those with HIV is impaired due to poor antibody response. I am currently co-leading an international multicenter ACTG trial to evaluate the efficacy and safety of a new hepatitis B vaccine. The vaccine uses a TLR-9 agonist and has not been previously studied in those with HIV infection.

#### Hepatitis E and HIV

Hepatitis E is a poorly recognized viral entity that is endemic in many resource-poor regions of the world. The HRG has extensively evaluated acute infections associated with HEV in the Nile River Valley. Our group has developed and modified diagnostic procedures for HEV and developed a framework for diagnosis (UpToDate, Schiff Textbook of Liver Disease, 2018). In those with HIV or immunosuppressed due to solid organ transplantation infection with a zoonotic form of HEV (Genotype 3) leads to a chronic infection with rapid progression of hepatic fibrosis. We have recently reported that up to 20% of patients with HIV awaiting liver or kidney transplantation in a national cohort have serologic evidence of HEV infection (J Viral Hepatitis, 2014). Most recently, we have documented a pattern of seroconversion and seroreversion which appears to be mediated in part by immune status. The implications of this are under investigation in two large cohorts. We are also developing new assays for serotyping of HEV infection.